WO2011002684A1 - Smac mimetic - Google Patents

Smac mimetic Download PDF

Info

Publication number
WO2011002684A1
WO2011002684A1 PCT/US2010/039976 US2010039976W WO2011002684A1 WO 2011002684 A1 WO2011002684 A1 WO 2011002684A1 US 2010039976 W US2010039976 W US 2010039976W WO 2011002684 A1 WO2011002684 A1 WO 2011002684A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
cell
tumors
carcinoma
Prior art date
Application number
PCT/US2010/039976
Other languages
French (fr)
Inventor
Stephen M. Condon
Yijun Deng
Matthew G. Laporte
Susan R. Rippin
Original Assignee
Tetralogic Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43411387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011002684(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2010266525A priority Critical patent/AU2010266525C1/en
Priority to EP10794587.5A priority patent/EP2448923B8/en
Priority to NZ597051A priority patent/NZ597051A/en
Priority to MX2011013819A priority patent/MX2011013819A/en
Priority to CN201080031798.6A priority patent/CN102471275B/en
Priority to US13/382,075 priority patent/US20120115922A1/en
Priority to DK10794587.5T priority patent/DK2448923T3/en
Priority to SG2011096948A priority patent/SG177404A1/en
Priority to EA201171494A priority patent/EA022061B1/en
Application filed by Tetralogic Pharmaceuticals Corp. filed Critical Tetralogic Pharmaceuticals Corp.
Priority to AP2012006066A priority patent/AP3619A/en
Priority to ES10794587.5T priority patent/ES2565337T3/en
Priority to UAA201200409A priority patent/UA108358C2/en
Priority to KR1020127001113A priority patent/KR101755218B1/en
Priority to JP2012518560A priority patent/JP5674780B2/en
Priority to CA2766162A priority patent/CA2766162C/en
Priority to BRPI1013958-3A priority patent/BRPI1013958B1/en
Publication of WO2011002684A1 publication Critical patent/WO2011002684A1/en
Priority to ZA2011/09342A priority patent/ZA201109342B/en
Priority to IL217237A priority patent/IL217237A/en
Priority to HK12110211.8A priority patent/HK1169410A1/en
Priority to HK12111923.5A priority patent/HK1171022A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention is in the field of SMAC mimetics and compositions and uses thereof to treat proliferative disorders including cancers.
  • IAPs Inhibitors of Apoptosis Proteins
  • SMAC also known as DIABLO
  • DIABLO is another intracellular protein that functions to antagonize, i.e., inhibit the activity of IAPs.
  • SMAC and IAPs function together to maintain healthy cells.
  • IAPs are not adequately antagonized and therefore prevent apoptosis and cause or exacerbate abnormal proliferation and survival.
  • SMAC mimetics also known as IAP antagonists, are synthetic small molecules that mimic the structure and IAP antagonist activity of the four N-terminal amino acids of SMAC.
  • SMAC mimetics are sometimes referred to as IAP antagonists.
  • the SMAC mimetics When administered to animals suffering proliferative disorders, the SMAC mimetics antagonize IAPs, causing an increase in apoptosis among abnormally proliferating cells.
  • SMAC peptidomimetics are those disclosed in US 7,517,906; US 7,309,792; US 7,419,975; US 2005/0234042; US 2005/0261203; US 2006/0014700; US 2006/0025347; US 2006/0052311 ; US 2006/0128632; US 2006/0167066; US 2007/0042428; US 2007/032437; US 2008/0132485; WO 2005/069888; WO 2005/069894; WO 2006/0101 18; WO
  • This invention in one aspect, is N- ⁇ lS-[2R-(6,6'-Difluoro-3'- ⁇ 4S-hydroxy-l-[2S-(2S- methylamino-propionylamino)-butyryl]-pyrrolidin-2R-ylmethyl ⁇ -lH,rH-[2,2']biindolyl-3- ylmethyl)-4S-hydroxy-pyrrolidine-l-carbonyl]-propyl ⁇ -2S-methylamino-propionamide and pharmaceutically acceptable salts thereof, as well as various forms of such compound and salts thereof as further described herein below.
  • This compound has the following structure:
  • R5 is -CH2CH3. This compound is also referred to herein as Compound 15.
  • the invention in related aspects, comprises a pharmaceutical composition comprising such compound and a method of treating a proliferative disorder in a human or non-human mammalian subject in need thereof that comprises internally administering to the subject an effective amount of said compound or a pharmaceutically acceptable salt thereof.
  • the invention comprises a method of treating a proliferative disorder in a mammal in need thereof, e.g., a human, or a companion animal, a food animal, or a sporting animal, that comprises internally administering to the animal an effective amount of Compound 15 or a pharmaceutically acceptable salt thereof.
  • the invention comprises a method for inducing apoptosis in a cell comprising contacting the cell with Compound 15 or a pharmaceutically acceptable salt thereof.
  • the cell can be, e.g., a cancerous cell.
  • the invention comprises any one or more of the above methods that further comprises administering a second cancer-related therapy, such as, e.g., radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.
  • a second cancer-related therapy such as, e.g., radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.
  • the invention comprises a method of treating an autoimmune disease, in which the condition is caused or exacerbated by abnormal regulation of apoptosis, in a mammal in need thereof, including, for example, systemic lupus erythematosus, psoriasis, and idiopathic thrombocytopenic purpura (Morbus Werlhof) that comprises internally administering to the animal an effective amount of Compound 15 or a pharmaceutically acceptable salt thereof.
  • a second cancer-related therapy such as, e.g., radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.
  • the invention comprises a method of treating an autoimmune disease, in which the condition
  • Figure 1 shows percent mean body weight loss in rat following 4 days of intravenous bolus dosing with SMAC mimetics substantially as described in Example 4.
  • Figure 2 shows mean tumor volume (2A) and body weight change (2B) resulting from treatment of human xenografts in nude mice with SMAC mimetics substantially as described in Example 5.
  • the compound of the invention is a SMAC mimetic that can be used in the treatment of proliferative disorders, e.g.: various benign tumors or malignant tumors (cancer), benign proliferative diseases (e.g., psoriasis, benign prostatic hypertrophy, and restenosis), or autoimmune diseases (e.g., autoimmune proliferative glomerulonephritis, lymphoproliferative autoimmune responses).
  • proliferative disorders e.g.: various benign tumors or malignant tumors (cancer), benign proliferative diseases (e.g., psoriasis, benign prostatic hypertrophy, and restenosis), or autoimmune diseases (e.g., autoimmune proliferative glomerulonephritis, lymphoproliferative autoimmune responses).
  • Cancers which potentially can be treated with IAP antagonists include, but are not limited to, one or more of the following: lung adenocarcinoma, pancreatic cancer, colon cancer, ovarian cancer, breast cancer, mesothelioma, peripheral neuroma, bladder cancer, glioblastoma, melanoma, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, bladder cancer, meningioma, glioma, astrocytoma, breast cancer, cervical cancer, chronic myeloproliferative disorders (e.g., chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lymphocytic leukemia, chronic lympho
  • myelogenous leukemia myelogenous leukemia
  • colon cancer endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gestational trophoblastic tumors, hairy cell leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, laryngeal cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, lip cancer, oral cavity cancer, liver cancer, male breast cancer, malignant mesothelioma, medulloblastoma, melanoma, Merkel cell carcinoma, metastatic squam
  • Some embodiments of the invention include inducing apoptosis of cells, particularly pathologically proliferating cells.
  • the methods can be carried out in vitro or in vivo.
  • the methods of the invention can include administration of the compound of the invention alone, administration of a combination of IAP antagonists, or administration of the compound of the invention, with or without one or more additional IAP antagonists, and one or more additional chemotherapeutic agents. Administration of multiple agents can be simultaneous or sequential.
  • chemotherapeutic agents include, but are not limited to, alkylating agents (e.g., cyclophosphamide, mechlorethamine, chlorambucil, melphalan), anthracyclines (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin), cytoskeletal disruptors (e.g., paclitaxel, docetaxel), epothilones (e.g., epothilone A, epothilone B, epothilone D), inhibitors of topoisomerase II (e.g., etoposide, teniposide, tafluposide), nucleotide analogs precursor analogs (e.g., azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcita
  • camptothecin etoposide, topotecan, irinotecan, cisplatin, carboplatin, oxaliplatin, amsacrine, mitoxantrone, 5-fluoro-uracil, or gemcitabine.
  • compositions comprising the compound of the invention, alone or in combination with one or more other active pharmaceutical ingredients, are administered to a human or veterinary subject.
  • the pharmaceutical compositions typically comprise at least one pharmaceutically acceptable excipient, e.g., a carrier or diluent, and can be administered in the conventional manner by routes including systemic, topical, or oral routes. Administration is normally by intravenous injection, either as a bolus or infusion, but other routes of administration are not precluded.
  • An intravenous formulation can be 1 mg/mL of Compound 15 in sterile 0.05M citrate buffered PBS, pH5. Specific modes of administration will depend on the indication and other factors including the particular compound being administered.
  • the amount of compound to be administered is that amount which is therapeutically effective.
  • the dosage to be administered will depend on the characteristics of the subject being treated, e.g., the particular patient treated, age, weight, health, types of concurrent treatment, if any.
  • Frequency of treatments can be easily determined by one of skill in the art (e.g., by the clinician).
  • the compound of the invention will be administered by intravenous injection, including, e.g., by infusion over about 1 to about 120 minutes, e.g., about 30 minutes.
  • the pharmaceutical composition of the invention is a composition in which the active pharmaceutical ingredient, i.e., the compound of the invention, is pure enough, and the composition is otherwise suitable, for internal administration to a human or other mammal. It can be prepared in unit dose form, i.e., a form suitable for single administration to a subject. So, e.g., a pharmaceutical composition in intra-venous unit dose form may comprise a vial or pre-filled syringe, each comprising an effective amount or a convenient fraction of an effective amount such that one the contents of one vial or syringe are administered at a time. Such administration can be repeated up to about 4 times per day over a period of time, if necessary to achieve a cumulative effective dose, e.g., tumor regression.
  • a cumulative effective dose e.g., tumor regression.
  • a dosing regimen can be, e.g., daily or twice-weekly intravenous injections, or, e.g., weekly injections in cycles of three weeks on and one week off for as long as the treatment is effective, e.g., until disease progresses or the drug is not tolerated.
  • the effective dose administered in each injection is an amount that is effective and tolerated; it can be, e.g., 0.01 to 30 mg/m , e.g., 0.2 to 10 mg/m , or, e.g., 0.5 to 5 mg/m .
  • the compound of the invention can also be applied locally, such as in isolated limb perfusion.
  • the compound of the invention can also be applied topically, e.g., as a cream, gel, lotion, or ointment, or in a reservoir or matrix-type patch, or in an active transdermal delivery system.
  • An effective dose is one that over the course of therapy, which may be, e.g., 1 or more weeks, e.g., multiple courses of 3 weeks on/1 week off, results in treatment of the proliferative disorder, i.e., a decrease in the rate of disease progression, termination of disease progression, or regression or remission.
  • Pharmaceutical compositions to be used comprise a therapeutically effective amount of a compound as described above, or a pharmaceutically acceptable salt or other form thereof together with one or more pharmaceutically acceptable excipients.
  • pharmaceutical composition refers to a composition suitable for administration in medical use. It should be appreciated that the determinations of proper dosage forms, dosage amounts, and routes of administration for a particular patient are within the level of ordinary skill in the pharmaceutical and medical arts.
  • compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the compound of the invention, which is preferably isotonic with the blood of the recipient.
  • This aqueous preparation may be formulated according to known methods using suitable carriers or diluents which may include a buffer.
  • the administration of the compound and compositions of the present invention can occur simultaneous with, subsequent to, or prior to chemotherapy or radiation, so long as the chemotherapeutic agent or radiation sensitizes the system to the compound and compositions of the present invention.
  • the present invention also is directed to the use of the compound and compositions as a chemopotentiating agent with other treatment approaches.
  • chemopotentiating agent refers to an agent that acts to increase the sensitivity of an organism, tissue, or cell to a chemical compound, or treatment namely "chemotherapeutic agents” or “chemo drugs” or to radiation treatment.
  • compound and compositions of the present invention can be used for inhibiting tumor growth in vivo by administering them in combination with a biologic or chemotherapeutic agent or by using them in combination with radiation.
  • the administration of the compound and compositions of the present invention may occur prior to, and with sufficient time, to cause sensitization of the site to be treated.
  • the compound and compositions of the present invention may be used contemporaneously with radiation and/or additional anti-cancer chemical agents (infra).
  • additional anti-cancer chemical agents infra
  • Such systems can avoid repeated administrations of the compound and compositions of the present invention, increasing convenience to the subject and the physician, and may be particularly suitable for certain compositions of the present invention.
  • Biological and chemotherapeutics/anti-neoplastic agents and radiation induce apoptosis by activating the extrinsic or intrinsic apoptotic pathways, and, since the compound and compositions of the present invention relieve antagonists of apoptotic proteins (IAPs) and, thus, remove the block in apoptosis, the combination of chemotherapeutics/anti-neoplastic agents and radiation with the compound and compositions of the present invention should work additively or synergistically to facilitate apoptosis.
  • IAPs antagonists of apoptotic proteins
  • chemotherapeutic/anti neoplastic agent and/or radiation therapy of any type that activates the extrinsic or intrinsic pathway may provide a more effective approach to destroying tumor cells.
  • the compound of the present invention interacts with IAP's, such as XIAP, cIAP-1, cIAP-2, ML-IAP, etc., and removes the IAP mediated block of apoptosis.
  • chemotherapeutics/anti neoplastic agents and/or radiation therapy kills actively dividing cells by activating the intrinsic apoptotic pathway leading to apoptosis and cell death.
  • Biological antitumor agents such as TRAIL (TNF-related apoptosis inducing ligand) activate extrinsic apoptotic pathways.
  • TRAIL TNF-related apoptosis inducing ligand
  • embodiments of the invention provide combinations of the compound of the present invention and a biological or chemotherapeutic/anti-neoplastic agent and/or radiation which provide a synergistic action against unwanted cell proliferation.
  • This synergistic action between the compound of the present invention and a biological or chemotherapeutic/anti-neoplastic agent and/or radiation therapy can improve the efficiency of the biological or chemotherapeutic/anti-neoplastic agent and/or radiation therapies.
  • This will allow for an increase in the effectiveness of current biological or chemotherapeutic/anti-neoplastic agents or radiation treatments allowing a higher percentage of tumors to respond to the therapy, an improved tumor response, and, potentially, a reduction in the dose of the biological or chemotherapeutic/anti-neoplastic agent needed to treat a tumor, thereby providing the use of a more tolerable dose of biological or chemotherapeutic/anti-neoplastic agent and/or radiation.
  • the patient is treated by administering the compound or a pharmaceutical composition of the present invention at a time the patient is subject to concurrent or antecedent radiation or chemotherapy for treatment of a
  • the compound or a composition of the present invention can be administered in combination with a biological or chemotherapeutic and/or for use in combination with radiotherapy, immunotherapy, and/or photodynamic therapy, promoting apoptosis and enhancing the effectiveness of the chemotherapeutic, radiotherapy, immunotherapy, and/or photodynamic therapy.
  • chemotherapeutic agent Such biological or chemotherapeutic agents include but are not limited to the chemotherapeutic agents described in "Modern Pharmacology with Clinical Applications", Sixth Edition, Craig & Stitzel, Chpt. 56, pg 639-656 (2004), herein incorporated by reference.
  • the chemotherapeutic agent can be, but is not limited to, alkylating agents, antimetabolites, anti-tumor antibiotics, plant-derived products such as taxanes, enzymes, hormonal agents, miscellaneous agents such as cisplatin, monoclonal antibodies, glucocorticoids, mitotic inhibitors, topoisomerase I inhibitors, topoisomerase II inhibitors, immunomodulating agents such as interferons, cellular growth factors, cytokines, and nonsteroidal anti-inflammatory compounds (NSAID), cellular growth factors and kinase inhibitors.
  • Other suitable classifications for chemotherapeutic agents include mitotic inhibitors,and anti-estrogenic agents.
  • Suitable biological and chemotherapeutic agents include, but are not limited to, cisplatin, carmustine (BCNU), 5-fluorouracil (5-FU), cytarabine (Ara-C), gemcitabine, methotrexate, daunorubicin, doxorubicin, dexamethasone, topotecan, etoposide, paclitaxel, vincristine, tamoxifen, TNF-alpha, TRAIL and other members, i.e., other than TRAIL and TNF-alpha, of the TNF superfamily of molecules., interferon (in both its alpha and beta forms), thalidomide, thalidomide derivatives such as lenalidomide, melphalan, and PARP inhibitors.
  • chemotherapeutic agents include nitrogen mustards such as cyclophosphamide, alkyl sulfonates, nitrosoureas, ethylenimines, triazenes, folate antagonists, purine analogs, pyrimidine analogs, anthracyclines, bleomycins, mitomycins, dactinomycins, plicamycin, vinca alkaloids, epipodophyllotoxins, taxanes, glucocorticoids, L-asparaginase, estrogens, androgens, progestins, luteinizing hormones, octreotide actetate, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, carboplatin, mitoxantrone, monoclonal antibodies, levamisole, interferons, interleukins, filgrastim and sargramostim.
  • nitrogen mustards such as cyclophosphamide, al
  • Another embodiment of the present invention relates to the use of the compound or a composition of the present invention in combination with topoisomerase inhibitors to potentiate their apoptotic inducing effect.
  • Topoisomerase inhibitors inhibit DNA replication and repair, thereby promoting apoptosis and are used as chemothemotherapeutic agents.
  • Topoisomerase inhibitors promote DNA damage by inhibiting the enzymes that are required in the DNA repair process. Therefore, export of Smac from the mitochondria into the cell cytosol is provoked by the DNA damage caused by topoisomerase inhibitors.
  • Topoisomerase inhibitors of both the Type I class (camptothecin, topotecan, SN-38 (irinotecan active metabolite) and the Type II class (etoposide) are expected to show potent synergy with compounds of the present invention.
  • Further examples of topoisomerase inhibiting agents that may be used include, but are not limited to, irinotecan, topotecan, etoposide, amsacrine, exatecan, gimatecan, etc.
  • Other topoisomerase inhibitors include, for example,
  • Aclacinomycin A camptothecin, daunorubicin, doxorubicin, ellipticine, epirubicin, and mitaxantrone.
  • Another embodiment of the present invention relates to the use of the compound or a composition of the present invention in combination with nonsteroidal antiinflammatory drugs (NSAIDs).
  • NSAIDs nonsteroidal antiinflammatory drugs
  • the chemotherapeutic/anti -neoplastic agent for use in combination with the compound and compositions of the present invention may be a platinum containing compound.
  • the platinum containing compound is cisplatin.
  • Cisplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, such as but not limited to XIAP, cIAP-1, c-IAP-2, ML- IAP, etc.
  • a platinum containing compound is carboplatin.
  • Carboplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, including, but not limited to, XIAP, cIAP-1, c-IAP-2, ML-IAP, etc.
  • a platinum containing compound is oxaliplatin.
  • the oxaliplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, including, but not limited to, XIAP, cIAP-1, c-IAP-2, ML-IAP, etc.
  • DNA modifying agents may be any highly reactive chemical compound that bonds with various nucleophilic groups in nucleic acids and proteins and cause mutagenic, carcinogenic, or cytotoxic effects.
  • DNA modifying agents work by different mechanisms, disruption of DNA function and cell death; DNA damage/the formation of cross-bridges or bonds between atoms in the DNA; and induction of mispairing of the nucleotides leading to mutations, to achieve the same end result.
  • Three non-limiting examples of a platinum containing DNA modifying agents are cisplatin, carboplatin and oxaliplatin.
  • Yet another embodiment of the present invention is the therapeutic combination or the therapeutic use in combination of the compound or compositions of the present invention with TRAIL or TRAIL agonist antibodies, or other chemical or biological agents which bind to and activate the TRAIL receptor(s).
  • TRAIL or TRAIL agonist antibodies or other chemical or biological agents which bind to and activate the TRAIL receptor(s).
  • Many cancer cell types are sensitive to TRAIL- induced apoptosis, while most normal cells appear to be resistant to this action of TRAIL.
  • TRAIL-resistant cells may arise by a variety of different mechanisms including loss of the receptor, presence of decoy receptors, overexpression of FLIP which competes for zymogen caspase-8 binding during DISC formation and inhibition of activated caspase-3 and/or caspase-9 by XIAP.
  • a compound or composition of the present invention may increase tumor cell sensitivity to TRAIL leading to enhanced cell death, the clinical correlations of which are expected to be increased apoptotic activity in TRAIL resistant tumors, improved clinical response, increased response duration, and ultimately, enhanced patient survival rate.
  • Compound 15 is administered in combination with a cytokine, e.g., TNF ⁇ .
  • a cytokine e.g., TNF ⁇ .
  • the compound and compositions of the present invention also can be used to augment radiation therapy (or radiotherapy), i.e., the medical use of ionizing radiation as part of cancer treatment to control malignant cells.
  • radiotherapy is often used as part of curative therapy, it is occasionally used as a palliative treatment, where cure is not possible and the aim is for symptomatic relief.
  • Radiotherapy is commonly used for the treatment of tumors. It may be used as the primary therapy. It is also common to combine radiotherapy with surgery and/or chemotherapy.
  • the most common tumors treated with radiotherapy are breast cancer, prostate cancer, rectal cancer, head & neck cancers, gynecological tumors, bladder cancer and lymphoma. Radiation therapy is commonly applied just to the localized area involved with the tumor.
  • the radiation fields also include the draining lymph nodes. It is possible but uncommon to give radiotherapy to the whole body, or entire skin surface. Radiation therapy is usually given daily for up to 35-38 fractions (a daily dose is a fraction). These small frequent doses allow healthy cells time to grow back, repairing damage inflicted by the radiation.
  • Three main divisions of radiotherapy are external beam radiotherapy or teletherapy, brachytherapy or sealed source radiotherapy and unsealed source radiotherapy, which are all suitable examples of treatment protocol in the present invention. The differences relate to the position of the radiation source; external is outside the body, while sealed and unsealed source radiotherapy has radioactive material delivered internally. Brachytherapy sealed sources are usually extracted later, while unsealed sources are injected into the body.
  • Compound 15 is capable of forming pharmaceutically acceptable salts, including but not limited to acid addition and/or base addition salts. Such salts are included within all aspects of the invention.
  • the present invention encompass Compound 15 synthesized in vitro using laboratory techniques, such as those well known to synthetic chemists; or synthesized using in vivo techniques, such as through metabolism, fermentation, digestion, and the like. It is also contemplated that the compound of the present invention maybe synthesized using a combination of in vitro and in vivo techniques.
  • the present invention also includes isotopically-enriched compounds, which are identical to Compound 15 but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be included in the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 16 O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 Cl. Substitution with heavier isotopes such as deuterium, i.e., 2 H, are also included.
  • Isotopically enriched compounds of this invention can generally be prepared by substituting a readily available isotopically labelled reagent for a non-isotopically enriched reagent.
  • incorporation of deuterium can be accomplished by substituting sodium borohydride with ⁇ -sodium borohydride, or by replacing iodomethane with ⁇ /3-iodomethane. Representative examples of specific deuterated analogs and their preparation are described in Example 1.
  • Compound 15 may exist in unsolvated forms as well as solvated forms, including hydrated forms. Furthermore, Compound 15 may exist in various solid states including crystalline, semi-crystalline and amorphous (noncrystalline) forms, and in the form of clathrates, prodrugs, polymorphs, bio-hydrolyzable esters, racemic mixtures, non-racemic mixtures, or as purified stereoisomers including, but not limited to, optically pure enantiomers and diastereomers. In general, all of these and other such forms are intended to be encompassed within the scope of the term, Compound 15.
  • references to Compound 15 and to the compound of the invention, and other similar phrases in this specification and in the claims, are intended to include not only the compound of formula (I), but also pharmaceutically acceptable salts of Compound 15, as well as various forms of said compound or salts thereof such as those that are described above and below.
  • the invention comprises compounds useful as intermediates in the synthesis of Compound 15, as well as in processes for preparing such intermediates and Compound 15.
  • the invention comprises compounds shown in the Examples, below, such as Compounds 9, 10, 1 1, 12, 13, 14, and the isotopically enriched compounds such as Compounds 18 through 32.
  • One such embodiment is
  • Compound 15 in which the 4-OH substituent on the pyrrolidine moiety is protected with a protecting group is an illustrative protecting group, which is illustrated in Compounds 11-14, below.
  • Other useful protecting groups will be apparent to persons of skill in the art and include, e.g., benzoyl, benzyl, trimethylsilyl, and triphenylmethyl groups.
  • the protecting group is removed, e.g., by contacting the protected intermediate with an acid or a base, as shown in Schemes XIII and XIV, below.
  • the invention comprises the compound having the structure of Compound 15 as well as protected versions of Compound 15 such as Compounds 13 and 14 in which the N-termini are protected with carbamate moieties and/or free hydroxyl groups are protected as esters such compounds being herein referred to as Protected Compound 15.
  • the invention further comprises the step of deprotecting a Protected Compound 15 by contacting the Protected Compound 15 with an acid or base whereby the Protecting Group is removed to afford Compound 15.
  • Isotopically enriched compounds of the invention include deuterated forms of Compound 15 such as Compounds 20, 29, and 32. Protected forms of such compounds, e.g., Compounds 19, 28, and 31, are also comprised within the invention.
  • 6-Fluoroindole (39.2 g, 290 mmol) was dissolved in anhydrous chlorobenzene (300 niL) and toluene (200 mL) and the solution was cooled to -4 0 C using an ice/acetone bath.
  • a solution of 3M EtMgBr in diethyl ether (101 g, 294 mmol) was added over 31 minutes at ⁇ 2.5 0 C resulting in a pale amber-colored solution.
  • the acid chloride/toluene solution (vide supra) was added over 45 minutes at ⁇ 2 0 C.
  • the reaction mixture was kept cold for 1 h then allowed to slowly warm. After ca.
  • the Celite® pad was further rinsed with THF (100 mL) which was concentrated in vacuo to provide another 1.12 g of 9 as a beige-colored solid.
  • the combined solids were dissolved in isopropyl acetate (iPrAc, 50 mL).
  • iPrAc isopropyl acetate
  • the iPrAc solution was reduced to ca. 20 mL and resulting suspension was warmed to reflux, cooled to ambient temperature, and then placed in an ice-bath. After 1 h, the solid was collected by vacuum filtration, washed with iPrAc (10 mL) and dried in a vacuum oven to afford 2.13 g (65%, 2 steps) of 9 as a beige- colored solid [Note: -100 A% by HPLC analysis].
  • reaction mixture was slowly warmed to ambient temperature. After 16 h, the reaction mixture was diluted with MTBE (1000 mL) and the heterogeneous mixture was washed with water (500 mL). The layers were separated and the organic phase formed a heterogeneous suspension. MTBE (1000 mL) and EtOAc (500 mL) were added and the now-homogeneous solution was washed successively with 1 N HCl (2 x 100 mL), saturated aqueous NaHCO 3 (2 x 100 mL), brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The residue was dissolved in 1 :1 DCM/ MeOH (600 mL) and DCM (ca.
  • the reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (200 mL) and extracted with EtOAc (500 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 150 mL). The combined organic extracts were washed with brine and dried over anhydrous Na 2 SO 4 , filtered, and concentrated to afford 22.5 g of crude 15 as a light, brown/yellow-colored solid.
  • the crude 15 (22.5 g) was dissolved in McOH (50 mL) and EtOAc (200 mL). The volume was reduced (50%) by distillation at reduced pressure at 60 0 C using a rotary evaporator. MTBE (300 mL) was added and the cloudy solution was warmed to 60 0 C. After 30 min, the solution was cooled to ambient temperature and then maintained at -5 0 C.
  • the DCM layer was separated and washed successively with dilute HCl (50 mL), water (50 mL), and brine (50 mL). The organic solution was dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by flash silica gel chromatography [30-40% EtOAc in hexane] to afford 2.0 g (62%, 2 steps) of 22 as a white foam.
  • the reaction mixture was slowly warmed to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (100 mL) and the mixture was washed successively with water (5 x 50 mL), IN HCl (50 mL), saturated aqueous NaHCO 3 (50 mL), and brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated.
  • the crude product was purified by reverse- phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product- containing fractions were combined, concentrated, and lyophilized to afford 310 mg of 25 (70%, 2 steps) as a flocculent white solid.
  • Acetic acid 5 (3'- ⁇ 4-acetoxy-l -[2-(2-methyl-ftert-butoxycarbonyl)-amino-propionylamino)- butyryli-pyrrolidin-2-yl- ⁇ -methvU -6,6'-difluoro- 1 H.1 ⁇ -[2,2'1biindolyl-3-yl- J r methylVl - [2-(2-methyl-(tert-butoxycarbonyl)-amino-propionylamino)-butyryl1-pyrrolidin-3-yl ester (27): To a solution containing Boc-N(Me)Ala-OH (83 mg, 0.41 mmol) and HATU (172 mg, 0.45 mmol) in anhydrous NMP (5 mL) at 0 0 C was added NMM (0.1 mL, 0.85 mmol) followed by addition of crude 26 (123 mg, 0.17 mmol) in NMP
  • the reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine and dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min).
  • the reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine and dried over anhydrous Na 2 SO 4 , filtered, and concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min).
  • the concentration inducing degradation of cIAP-1 and cIAP-2 by 50% (IC 50 ) for various compounds was determined by monitoring the disappearance of Green Fluorescent Protein (GFP)-signal in A375 cells.
  • GFP Green Fluorescent Protein
  • A375 cell lines expressing GFP-tagged cIAP-1 and cIAP-2 were generated by transfecting HA2xEGFP-pcDNA3 vector containing either cIAP-1 (A375Gcl) or cIAP-2 (A375Gc2) coding region. 2xlO 4 of A375Gcl or A375Gc2 cells were grown in 96-well plate and treated with various concentrations of test compounds for 2 h.
  • IC 50 is defined as the concentration of drug at which 50% of GFP signal was inhibited.
  • Exponentially growing MDA-MB-231 tumor cells were harvested by trypsinization and collected by centrifugation in a table top centrifuge at 1000xg for 10 minutes at room temperature. Cell pellet was washed one time by resuspending in 5 mL hypotonic lysis buffer (20 mM HEPES, pH7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1.0 mM EDTA, 1.0 mM DTT) and recollected by centrifugation. Pellet was next resuspended in 1 volume of hypotonic lysis buffer supplemented with a complete protease inhibitor tablet (Roche) and allowed to swell on ice for 30 minutes.
  • hypotonic lysis buffer (20 mM HEPES, pH7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1.0 mM EDTA, 1.0 mM DTT
  • Endogenous XIAP inhibits much of this activity and addition of test compound to the activated lysate results in more caspase activity than is generated by activated lysate alone as measured by increase in fluorescence intensity upon cleavage of zD E VD-Rl 10( 2 ) by caspase- 3.
  • IC 50 values were calculated using GraphPad Prism by plotting increase in fluorescence intensity vs. different concentrations of compounds tested and the results are shown in Table 3.
  • MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
  • MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
  • SK-OV-3 cells were seeded in 96- well plates in McCoy's medium containing 10% fetal bovine serum albumin (5,000 per well) and incubated overnight at 37°C.
  • test compounds were added at various concentrations (0.003-10 ⁇ M) and the plates were incubated at 37°C for an additional 72 hrs. This incubation time was optimal for measuring inhibitory effects of different analogs. Fifty microliters of 5mg/mL MTT reagent to each well was added and the plates were incubated at 37°C for 3 hours. At the end of the incubation period, 50 microliters of DMSO was added to each well to dissolve cells and the optical density (OD) of the wells was measured using a microplate reader (Victor 2 1420, Wallac, Finland) at 535 nm. Cell survival (CS) was calculated by the following equation:
  • the CC 50 defined as the drug concentration that results in 50% CS, was derived by calculating the point where the dose-response curve crosses the 50% CS point using
  • Body weight loss (BWL), mortality and additional toxicity data were generated substantially as follows. Sprague-Dawley rats were dosed daily (QDx4, i.v. bolus slow push) with
  • Compounds 15, 4 and 5 Body weights were taken on day 4 and are shown as percent change from day 1. Compounds 4 and 5 were administered at 0.3 mg/Kg, 1 mg/Kg, or 3 mg/Kg;
  • Compound 15 was administered at 1 , 5, or 10 mg/Kg.
  • Body Weight At 1 mg/Kg, animals receiving Compounds 4 and 5 lost weight whereas animals receiving Compound 15 at 1 mg/kg/day gained weight. At 5 mg/kg/day with Compound 15, a treatment related mean body weight loss of approximately 8% was noted from day 1 to day 4. A treatment-related mean body weight loss of approximately 4 % and 6 % was noted in animals treated with Compounds 4 and 5, respectively, at 1 mg/kg/day.
  • Pathology Assessment of anatomic pathology after treatment with Compounds 4 and 5 at 1 mg/kg/day resulted in the following findings.
  • hypotrophied bronchiolar epithelium proliferating perivascular mononuclear cells and hypertrophied visceral pleural cells.
  • assessment of anatomic pathology following treatment with Compound 15 at the same dose (1 mg/kg/day) identified minimal to mild hypocellularity of erythroid cells, minimal to mild hypercellularity of myeloid cells, and minimal Type 2 pneumocyte hypertrophy in the lungs.
  • MDA-MB-231 xenograft data were generated substantially as follows.
  • MDA-MB-231 human breast tumor cells were injected into the mammary fat pad of female nude mice and dosing initiated twelve days later at an average tumor volume of approximately 148 mm 3 . No tumor burden was associated with this model based on lack of weight loss or animal morbidity in control groups.
  • Mice were injected subcutaneously into the mammary fat pad with 1x10 7 cells suspended in 200 ⁇ l of a 1 :1 HBSS: Matrigel solution ; injected cells were within nine passages of the original lot.
  • Pre-study tumor volumes were recorded beginning approximately one week prior to the estimated start date. When tumors reached
  • mice are matched by tumor volume into treatment and control groups and dosing initiated (Day 0); mice are tagged and followed individually throughout the experiment. Animals were dosed by weight (0.01 mL per gram; 10 ml/Kg).
  • mice were observed daily and weighed twice weekly using a digital scale (Ohaus SP601); data including individual and mean gram weights (Mean We ⁇ SD), mean percent weight change versus Day 0 (%vDo) and mean percent weight change versus prior measurement (%vD. x ) were recorded for each group and plotted at study completion.
  • tumor dimensions were measured twice weekly by digital caliper (Fowler Ultra-Cal IV) and data including individual and mean estimated tumor volumes (Mean TV ⁇ SEM) recorded for each group; tumor volume was calculated using the formula: TV ⁇ width ' x length x 0.52.
  • TTE time to endpoint
  • TGD tumor growth delay
  • LTS long-term survivors
  • TTE tumor-free animals are not included in TGD calculations.
  • mice lacking palpable tumors were classified as complete responders (CR); a CR that persisted until study completion was considered a tumor-free survivor (TFS); TFS animals are excluded from TGD calculations and statistical analysis.
  • CR complete responders
  • TFS tumor-free survivor
  • 6/10 mice were considered long-term survivors and partial tumor regression was reported in three mice.
  • 40 mg/Kg group 9/10 mice were considered long-term survivors and partial tumor regression was reported in three mice.
  • Compound 5 was administered by i.p.
  • Compound 15 at 20 mg/Kg had comparable anti-tumor activity to Compound 5 at 15 mg/Kg. Subsequent studies have shown that the minimal effective dose of Compound 15 in this model is less than 1 mg/Kg. Weight loss was greater in the mice administered Compound 5 at 15 mg/Kg when compared to the mice dosed with Compound 15 at 20 mg/Kg. Thus, Compound 15 has comparable efficacy with less toxicity relative to Compound 5 and therefore has an improved therapeutic index.
  • the compound of Formula 1 is particularly well tolerated and well suited for use in a pharmaceutical composition, as well as in a method for treating a proliferative disorder or an autoimmune disorder.
  • the pharmaceutical composition of the invention for the treatment of a proliferative disorder which comprises an effective amount of Compound 15 in addition to at least one pharmaceutically acceptable excipient, can improve therapeutic index by reducing toxicities.
  • the reduced toxicities include, e.g., one of, or any combination of one or more of:
  • the reduced toxicities listed above are those observed in the animals tested. Similar, additional, or different reduced toxicities will be observed in humans.
  • the reductions are relative, e.g., relative to the extent that toxicities would be observed following internal administration of a pharmaceutical composition in which the active pharmaceutical ingredient is an analog of Compound 15, e.g., one or more of the analogs in which R5 is -CH2CH3, - CH(CH3)CH3, -tf-CH(OH)CH3, -S-CH(OH)CH3, and -7?-CH(OCH3)CH3, e.g., at the same dose or at a dose of comparable potency.
  • the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Description

SMAC MIMETIC
Field of the Invention
This invention is in the field of SMAC mimetics and compositions and uses thereof to treat proliferative disorders including cancers.
Background of the Invention
Inhibitors of Apoptosis Proteins (IAPs) are naturally occurring intra-cellular proteins that suppress caspase-dependent apoptosis. SMAC, also known as DIABLO, is another intracellular protein that functions to antagonize, i.e., inhibit the activity of IAPs. In normal healthy cells, SMAC and IAPs function together to maintain healthy cells. However, in certain disease states, e.g., cancers and other proliferative disorders, IAPs are not adequately antagonized and therefore prevent apoptosis and cause or exacerbate abnormal proliferation and survival.
SMAC mimetics, also known as IAP antagonists, are synthetic small molecules that mimic the structure and IAP antagonist activity of the four N-terminal amino acids of SMAC.
(SMAC mimetics are sometimes referred to as IAP antagonists.) When administered to animals suffering proliferative disorders, the SMAC mimetics antagonize IAPs, causing an increase in apoptosis among abnormally proliferating cells.
Examples of SMAC peptidomimetics are those disclosed in US 7,517,906; US 7,309,792; US 7,419,975; US 2005/0234042; US 2005/0261203; US 2006/0014700; US 2006/0025347; US 2006/0052311 ; US 2006/0128632; US 2006/0167066; US 2007/0042428; US 2007/032437; US 2008/0132485; WO 2005/069888; WO 2005/069894; WO 2006/0101 18; WO
2006/122408; WO 2006/017295; WO 2006/133147; WO 2006/128455; WO 2006/091972; WO 2006/020060; WO 2006/014361; WO 2006/097791; WO 2005/094818; WO
2008/045905; WO 2008/016893; WO 2007/136921; WO 2007/021825; WO 2007/130626; WO 2007/106192; and WO 2007/101347.
Summary of the Invention
This invention, in one aspect, is N-{lS-[2R-(6,6'-Difluoro-3'-{4S-hydroxy-l-[2S-(2S- methylamino-propionylamino)-butyryl]-pyrrolidin-2R-ylmethyl}-lH,rH-[2,2']biindolyl-3- ylmethyl)-4S-hydroxy-pyrrolidine-l-carbonyl]-propyl}-2S-methylamino-propionamide and pharmaceutically acceptable salts thereof, as well as various forms of such compound and salts thereof as further described herein below.
This compound has the following structure:
Figure imgf000003_0001
wherein R5 is -CH2CH3. This compound is also referred to herein as Compound 15.
The invention, in related aspects, comprises a pharmaceutical composition comprising such compound and a method of treating a proliferative disorder in a human or non-human mammalian subject in need thereof that comprises internally administering to the subject an effective amount of said compound or a pharmaceutically acceptable salt thereof.
In other aspects, the invention comprises a method of treating a proliferative disorder in a mammal in need thereof, e.g., a human, or a companion animal, a food animal, or a sporting animal, that comprises internally administering to the animal an effective amount of Compound 15 or a pharmaceutically acceptable salt thereof.
In another illustrative embodiment, the invention comprises a method for inducing apoptosis in a cell comprising contacting the cell with Compound 15 or a pharmaceutically acceptable salt thereof. In this embodiment, the cell can be, e.g., a cancerous cell.
In additional illustrative embodiments, the invention comprises any one or more of the above methods that further comprises administering a second cancer-related therapy, such as, e.g., radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof. In a further illustrative embodiment, the invention comprises a method of treating an autoimmune disease, in which the condition is caused or exacerbated by abnormal regulation of apoptosis, in a mammal in need thereof, including, for example, systemic lupus erythematosus, psoriasis, and idiopathic thrombocytopenic purpura (Morbus Werlhof) that comprises internally administering to the animal an effective amount of Compound 15 or a pharmaceutically acceptable salt thereof.
Brief Description of the Figures
Figure 1 shows percent mean body weight loss in rat following 4 days of intravenous bolus dosing with SMAC mimetics substantially as described in Example 4.
Figure 2 shows mean tumor volume (2A) and body weight change (2B) resulting from treatment of human xenografts in nude mice with SMAC mimetics substantially as described in Example 5.
Detailed Description of the Invention
The compound of the invention is a SMAC mimetic that can be used in the treatment of proliferative disorders, e.g.: various benign tumors or malignant tumors (cancer), benign proliferative diseases (e.g., psoriasis, benign prostatic hypertrophy, and restenosis), or autoimmune diseases (e.g., autoimmune proliferative glomerulonephritis, lymphoproliferative autoimmune responses). Cancers which potentially can be treated with IAP antagonists include, but are not limited to, one or more of the following: lung adenocarcinoma, pancreatic cancer, colon cancer, ovarian cancer, breast cancer, mesothelioma, peripheral neuroma, bladder cancer, glioblastoma, melanoma, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, bladder cancer, meningioma, glioma, astrocytoma, breast cancer, cervical cancer, chronic myeloproliferative disorders (e.g., chronic lymphocytic leukemia, chronic
myelogenous leukemia), colon cancer, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gestational trophoblastic tumors, hairy cell leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, laryngeal cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, lip cancer, oral cavity cancer, liver cancer, male breast cancer, malignant mesothelioma, medulloblastoma, melanoma, Merkel cell carcinoma, metastatic squamous neck cancer, multiple myeloma and other plasma cell neoplasms, mycosis fungoides and the Sezary syndrome, myelodysplastic syndromes, nasopharyngeal cancer, neuroblastoma, non- small cell lung cancer, small cell lung cancer, oropharyngeal cancer, bone cancers, including osteosarcoma and malignant fibrous histiocytoma of bone, ovarian epithelial cancer, ovarian germ cell tumors, ovarian low malignant potential tumors, pancreatic cancer, paranasal sinus cancer, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumors, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, supratentorial primitive neuroectodermal tumors, pineoblastoma, testicular cancer, thymoma, thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilm's tumor and other childhood kidney tumors.
Some embodiments of the invention include inducing apoptosis of cells, particularly pathologically proliferating cells. The methods can be carried out in vitro or in vivo.
The methods of the invention can include administration of the compound of the invention alone, administration of a combination of IAP antagonists, or administration of the compound of the invention, with or without one or more additional IAP antagonists, and one or more additional chemotherapeutic agents. Administration of multiple agents can be simultaneous or sequential. Useful chemotherapeutic agents include, but are not limited to, alkylating agents (e.g., cyclophosphamide, mechlorethamine, chlorambucil, melphalan), anthracyclines (e.g., daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin), cytoskeletal disruptors (e.g., paclitaxel, docetaxel), epothilones (e.g., epothilone A, epothilone B, epothilone D), inhibitors of topoisomerase II (e.g., etoposide, teniposide, tafluposide), nucleotide analogs precursor analogs (e.g., azacitidine, azathioprine, capecitabine, cytarabine, doxifluridine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, tioguanine), peptide antibiotics (e.g., bleomycin), platinum-based agents (e.g., carboplatin, cisplatin, oxaliplatin), retinoids (e.g., all-trans retinoic acid), and vinca alkaloids and derivatives (e.g., vinblastine, vincristine, vindesine, vinorelbine). In some embodiments, chemotherapeutic agents include fludarabine, doxorubicin, paclitaxel, docetaxel,
camptothecin, etoposide, topotecan, irinotecan, cisplatin, carboplatin, oxaliplatin, amsacrine, mitoxantrone, 5-fluoro-uracil, or gemcitabine.
In some embodiments of the invention, pharmaceutical compositions comprising the compound of the invention, alone or in combination with one or more other active pharmaceutical ingredients, are administered to a human or veterinary subject. The pharmaceutical compositions typically comprise at least one pharmaceutically acceptable excipient, e.g., a carrier or diluent, and can be administered in the conventional manner by routes including systemic, topical, or oral routes. Administration is normally by intravenous injection, either as a bolus or infusion, but other routes of administration are not precluded. An intravenous formulation can be 1 mg/mL of Compound 15 in sterile 0.05M citrate buffered PBS, pH5. Specific modes of administration will depend on the indication and other factors including the particular compound being administered. The amount of compound to be administered is that amount which is therapeutically effective. The dosage to be administered will depend on the characteristics of the subject being treated, e.g., the particular patient treated, age, weight, health, types of concurrent treatment, if any.
Frequency of treatments can be easily determined by one of skill in the art (e.g., by the clinician).
Typically, the compound of the invention will be administered by intravenous injection, including, e.g., by infusion over about 1 to about 120 minutes, e.g., about 30 minutes.
The pharmaceutical composition of the invention is a composition in which the active pharmaceutical ingredient, i.e., the compound of the invention, is pure enough, and the composition is otherwise suitable, for internal administration to a human or other mammal. It can be prepared in unit dose form, i.e., a form suitable for single administration to a subject. So, e.g., a pharmaceutical composition in intra-venous unit dose form may comprise a vial or pre-filled syringe, each comprising an effective amount or a convenient fraction of an effective amount such that one the contents of one vial or syringe are administered at a time. Such administration can be repeated up to about 4 times per day over a period of time, if necessary to achieve a cumulative effective dose, e.g., tumor regression. A dosing regimen can be, e.g., daily or twice-weekly intravenous injections, or, e.g., weekly injections in cycles of three weeks on and one week off for as long as the treatment is effective, e.g., until disease progresses or the drug is not tolerated. The effective dose administered in each injection is an amount that is effective and tolerated; it can be, e.g., 0.01 to 30 mg/m , e.g., 0.2 to 10 mg/m , or, e.g., 0.5 to 5 mg/m .
The compound of the invention can also be applied locally, such as in isolated limb perfusion. The compound of the invention can also be applied topically, e.g., as a cream, gel, lotion, or ointment, or in a reservoir or matrix-type patch, or in an active transdermal delivery system.
An effective dose is one that over the course of therapy, which may be, e.g., 1 or more weeks, e.g., multiple courses of 3 weeks on/1 week off, results in treatment of the proliferative disorder, i.e., a decrease in the rate of disease progression, termination of disease progression, or regression or remission. Pharmaceutical compositions to be used comprise a therapeutically effective amount of a compound as described above, or a pharmaceutically acceptable salt or other form thereof together with one or more pharmaceutically acceptable excipients. The phrase
"pharmaceutical composition" refers to a composition suitable for administration in medical use. It should be appreciated that the determinations of proper dosage forms, dosage amounts, and routes of administration for a particular patient are within the level of ordinary skill in the pharmaceutical and medical arts.
Compositions suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the compound of the invention, which is preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable carriers or diluents which may include a buffer.
When practicing the conjoint or combination therapy described in more detail below, the administration of the compound and compositions of the present invention can occur simultaneous with, subsequent to, or prior to chemotherapy or radiation, so long as the chemotherapeutic agent or radiation sensitizes the system to the compound and compositions of the present invention.
The present invention also is directed to the use of the compound and compositions as a chemopotentiating agent with other treatment approaches. The term "chemopotentiating agent" refers to an agent that acts to increase the sensitivity of an organism, tissue, or cell to a chemical compound, or treatment namely "chemotherapeutic agents" or "chemo drugs" or to radiation treatment. Thus, compound and compositions of the present invention can be used for inhibiting tumor growth in vivo by administering them in combination with a biologic or chemotherapeutic agent or by using them in combination with radiation. In these
applications, the administration of the compound and compositions of the present invention may occur prior to, and with sufficient time, to cause sensitization of the site to be treated. Alternatively, the compound and compositions of the present invention may be used contemporaneously with radiation and/or additional anti-cancer chemical agents (infra). Such systems can avoid repeated administrations of the compound and compositions of the present invention, increasing convenience to the subject and the physician, and may be particularly suitable for certain compositions of the present invention.
Biological and chemotherapeutics/anti-neoplastic agents and radiation induce apoptosis by activating the extrinsic or intrinsic apoptotic pathways, and, since the compound and compositions of the present invention relieve antagonists of apoptotic proteins (IAPs) and, thus, remove the block in apoptosis, the combination of chemotherapeutics/anti-neoplastic agents and radiation with the compound and compositions of the present invention should work additively or synergistically to facilitate apoptosis.
A combination of the compound of the present invention and a biological or
chemotherapeutic/anti neoplastic agent and/or radiation therapy of any type that activates the extrinsic or intrinsic pathway may provide a more effective approach to destroying tumor cells. The compound of the present invention interacts with IAP's, such as XIAP, cIAP-1, cIAP-2, ML-IAP, etc., and removes the IAP mediated block of apoptosis. Most
chemotherapeutics/anti neoplastic agents and/or radiation therapy kills actively dividing cells by activating the intrinsic apoptotic pathway leading to apoptosis and cell death. Biological antitumor agents such as TRAIL (TNF-related apoptosis inducing ligand) activate extrinsic apoptotic pathways. As is described in more detail below, embodiments of the invention provide combinations of the compound of the present invention and a biological or chemotherapeutic/anti-neoplastic agent and/or radiation which provide a synergistic action against unwanted cell proliferation. This synergistic action between the compound of the present invention and a biological or chemotherapeutic/anti-neoplastic agent and/or radiation therapy can improve the efficiency of the biological or chemotherapeutic/anti-neoplastic agent and/or radiation therapies. This will allow for an increase in the effectiveness of current biological or chemotherapeutic/anti-neoplastic agents or radiation treatments allowing a higher percentage of tumors to respond to the therapy, an improved tumor response, and, potentially, a reduction in the dose of the biological or chemotherapeutic/anti-neoplastic agent needed to treat a tumor, thereby providing the use of a more tolerable dose of biological or chemotherapeutic/anti-neoplastic agent and/or radiation.
In an embodiment of the present invention, the patient is treated by administering the compound or a pharmaceutical composition of the present invention at a time the patient is subject to concurrent or antecedent radiation or chemotherapy for treatment of a
neoproliferative pathology of a tumor such as, but not limited to, bladder cancer, breast cancer, prostate cancer, lung cancer, pancreatic cancer, gastric cancer, colon cancer, ovarian cancer, renal cancer, hepatoma, melanoma, lymphoma, sarcoma, and combinations thereof. In another embodiment of the present invention, the compound or a composition of the present invention can be administered in combination with a biological or chemotherapeutic and/or for use in combination with radiotherapy, immunotherapy, and/or photodynamic therapy, promoting apoptosis and enhancing the effectiveness of the chemotherapeutic, radiotherapy, immunotherapy, and/or photodynamic therapy.
Embodiments of the invention also include a method of treating a patient afflicted with cancer by the contemporaneous or concurrent administration of a biological or
chemotherapeutic agent. Such biological or chemotherapeutic agents include but are not limited to the chemotherapeutic agents described in "Modern Pharmacology with Clinical Applications", Sixth Edition, Craig & Stitzel, Chpt. 56, pg 639-656 (2004), herein incorporated by reference. The chemotherapeutic agent can be, but is not limited to, alkylating agents, antimetabolites, anti-tumor antibiotics, plant-derived products such as taxanes, enzymes, hormonal agents, miscellaneous agents such as cisplatin, monoclonal antibodies, glucocorticoids, mitotic inhibitors, topoisomerase I inhibitors, topoisomerase II inhibitors, immunomodulating agents such as interferons, cellular growth factors, cytokines, and nonsteroidal anti-inflammatory compounds (NSAID), cellular growth factors and kinase inhibitors. Other suitable classifications for chemotherapeutic agents include mitotic inhibitors,and anti-estrogenic agents.
Specific examples of suitable biological and chemotherapeutic agents include, but are not limited to, cisplatin, carmustine (BCNU), 5-fluorouracil (5-FU), cytarabine (Ara-C), gemcitabine, methotrexate, daunorubicin, doxorubicin, dexamethasone, topotecan, etoposide, paclitaxel, vincristine, tamoxifen, TNF-alpha, TRAIL and other members, i.e., other than TRAIL and TNF-alpha, of the TNF superfamily of molecules., interferon (in both its alpha and beta forms), thalidomide, thalidomide derivatives such as lenalidomide, melphalan, and PARP inhibitors. Other specific examples of suitable chemotherapeutic agents include nitrogen mustards such as cyclophosphamide, alkyl sulfonates, nitrosoureas, ethylenimines, triazenes, folate antagonists, purine analogs, pyrimidine analogs, anthracyclines, bleomycins, mitomycins, dactinomycins, plicamycin, vinca alkaloids, epipodophyllotoxins, taxanes, glucocorticoids, L-asparaginase, estrogens, androgens, progestins, luteinizing hormones, octreotide actetate, hydroxyurea, procarbazine, mitotane, hexamethylmelamine, carboplatin, mitoxantrone, monoclonal antibodies, levamisole, interferons, interleukins, filgrastim and sargramostim.
Another embodiment of the present invention relates to the use of the compound or a composition of the present invention in combination with topoisomerase inhibitors to potentiate their apoptotic inducing effect. Topoisomerase inhibitors inhibit DNA replication and repair, thereby promoting apoptosis and are used as chemothemotherapeutic agents. Topoisomerase inhibitors promote DNA damage by inhibiting the enzymes that are required in the DNA repair process. Therefore, export of Smac from the mitochondria into the cell cytosol is provoked by the DNA damage caused by topoisomerase inhibitors. Topoisomerase inhibitors of both the Type I class (camptothecin, topotecan, SN-38 (irinotecan active metabolite) and the Type II class (etoposide) are expected to show potent synergy with compounds of the present invention. Further examples of topoisomerase inhibiting agents that may be used include, but are not limited to, irinotecan, topotecan, etoposide, amsacrine, exatecan, gimatecan, etc. Other topoisomerase inhibitors include, for example,
Aclacinomycin A, camptothecin, daunorubicin, doxorubicin, ellipticine, epirubicin, and mitaxantrone.
Another embodiment of the present invention relates to the use of the compound or a composition of the present invention in combination with nonsteroidal antiinflammatory drugs (NSAIDs).
In another embodiment of the invention, the chemotherapeutic/anti -neoplastic agent for use in combination with the compound and compositions of the present invention may be a platinum containing compound. In one embodiment of the invention, the platinum containing compound is cisplatin. Cisplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, such as but not limited to XIAP, cIAP-1, c-IAP-2, ML- IAP, etc. In another embodiment a platinum containing compound is carboplatin.
Carboplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, including, but not limited to, XIAP, cIAP-1, c-IAP-2, ML-IAP, etc. In another embodiment a platinum containing compound is oxaliplatin. The oxaliplatin can synergize with a compound of the present invention and potentiate the inhibition of an IAP, including, but not limited to, XIAP, cIAP-1, c-IAP-2, ML-IAP, etc.
Platinum chemotherapy drugs belong to a general group of DNA modifying agents. DNA modifying agents may be any highly reactive chemical compound that bonds with various nucleophilic groups in nucleic acids and proteins and cause mutagenic, carcinogenic, or cytotoxic effects. DNA modifying agents work by different mechanisms, disruption of DNA function and cell death; DNA damage/the formation of cross-bridges or bonds between atoms in the DNA; and induction of mispairing of the nucleotides leading to mutations, to achieve the same end result. Three non-limiting examples of a platinum containing DNA modifying agents are cisplatin, carboplatin and oxaliplatin. Yet another embodiment of the present invention is the therapeutic combination or the therapeutic use in combination of the compound or compositions of the present invention with TRAIL or TRAIL agonist antibodies, or other chemical or biological agents which bind to and activate the TRAIL receptor(s). Many cancer cell types are sensitive to TRAIL- induced apoptosis, while most normal cells appear to be resistant to this action of TRAIL. TRAIL-resistant cells may arise by a variety of different mechanisms including loss of the receptor, presence of decoy receptors, overexpression of FLIP which competes for zymogen caspase-8 binding during DISC formation and inhibition of activated caspase-3 and/or caspase-9 by XIAP. In TRAIL resistance, a compound or composition of the present invention may increase tumor cell sensitivity to TRAIL leading to enhanced cell death, the clinical correlations of which are expected to be increased apoptotic activity in TRAIL resistant tumors, improved clinical response, increased response duration, and ultimately, enhanced patient survival rate.
In another embodiment of the invention, Compound 15 is administered in combination with a cytokine, e.g., TNFα.
The compound and compositions of the present invention also can be used to augment radiation therapy (or radiotherapy), i.e., the medical use of ionizing radiation as part of cancer treatment to control malignant cells. Although radiotherapy is often used as part of curative therapy, it is occasionally used as a palliative treatment, where cure is not possible and the aim is for symptomatic relief. Radiotherapy is commonly used for the treatment of tumors. It may be used as the primary therapy. It is also common to combine radiotherapy with surgery and/or chemotherapy. The most common tumors treated with radiotherapy are breast cancer, prostate cancer, rectal cancer, head & neck cancers, gynecological tumors, bladder cancer and lymphoma. Radiation therapy is commonly applied just to the localized area involved with the tumor. Often the radiation fields also include the draining lymph nodes. It is possible but uncommon to give radiotherapy to the whole body, or entire skin surface. Radiation therapy is usually given daily for up to 35-38 fractions (a daily dose is a fraction). These small frequent doses allow healthy cells time to grow back, repairing damage inflicted by the radiation. Three main divisions of radiotherapy are external beam radiotherapy or teletherapy, brachytherapy or sealed source radiotherapy and unsealed source radiotherapy, which are all suitable examples of treatment protocol in the present invention. The differences relate to the position of the radiation source; external is outside the body, while sealed and unsealed source radiotherapy has radioactive material delivered internally. Brachytherapy sealed sources are usually extracted later, while unsealed sources are injected into the body.
Compound 15 is capable of forming pharmaceutically acceptable salts, including but not limited to acid addition and/or base addition salts. Such salts are included within all aspects of the invention.
It is intended that the present invention encompass Compound 15 synthesized in vitro using laboratory techniques, such as those well known to synthetic chemists; or synthesized using in vivo techniques, such as through metabolism, fermentation, digestion, and the like. It is also contemplated that the compound of the present invention maybe synthesized using a combination of in vitro and in vivo techniques.
The present invention also includes isotopically-enriched compounds, which are identical to Compound 15 but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be included in the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 16O, 170, 31P, 32P, 35S, 18F, and 36Cl. Substitution with heavier isotopes such as deuterium, i.e., 2H, are also included. Isotopically enriched compounds of this invention can generally be prepared by substituting a readily available isotopically labelled reagent for a non-isotopically enriched reagent. For example, incorporation of deuterium can be accomplished by substituting sodium borohydride with ^-sodium borohydride, or by replacing iodomethane with ^/3-iodomethane. Representative examples of specific deuterated analogs and their preparation are described in Example 1.
Compound 15 may exist in unsolvated forms as well as solvated forms, including hydrated forms. Furthermore, Compound 15 may exist in various solid states including crystalline, semi-crystalline and amorphous (noncrystalline) forms, and in the form of clathrates, prodrugs, polymorphs, bio-hydrolyzable esters, racemic mixtures, non-racemic mixtures, or as purified stereoisomers including, but not limited to, optically pure enantiomers and diastereomers. In general, all of these and other such forms are intended to be encompassed within the scope of the term, Compound 15.
References to Compound 15 and to the compound of the invention, and other similar phrases in this specification and in the claims, are intended to include not only the compound of formula (I), but also pharmaceutically acceptable salts of Compound 15, as well as various forms of said compound or salts thereof such as those that are described above and below. In additional embodiments, the invention comprises compounds useful as intermediates in the synthesis of Compound 15, as well as in processes for preparing such intermediates and Compound 15. For example, in such embodiments, the invention comprises compounds shown in the Examples, below, such as Compounds 9, 10, 1 1, 12, 13, 14, and the isotopically enriched compounds such as Compounds 18 through 32. One such embodiment is
Compound 15 in which the 4-OH substituent on the pyrrolidine moiety is protected with a protecting group. An illustrative protecting group is an acetyl group, which is illustrated in Compounds 11-14, below. Other useful protecting groups will be apparent to persons of skill in the art and include, e.g., benzoyl, benzyl, trimethylsilyl, and triphenylmethyl groups. The protecting group is removed, e.g., by contacting the protected intermediate with an acid or a base, as shown in Schemes XIII and XIV, below. Thus, the invention comprises the compound having the structure of Compound 15 as well as protected versions of Compound 15 such as Compounds 13 and 14 in which the N-termini are protected with carbamate moieties and/or free hydroxyl groups are protected as esters such compounds being herein referred to as Protected Compound 15. The invention further comprises the step of deprotecting a Protected Compound 15 by contacting the Protected Compound 15 with an acid or base whereby the Protecting Group is removed to afford Compound 15. Isotopically enriched compounds of the invention include deuterated forms of Compound 15 such as Compounds 20, 29, and 32. Protected forms of such compounds, e.g., Compounds 19, 28, and 31, are also comprised within the invention.
Examples
The following preparations and schemes are illustrative of synthesis of compounds of the present invention. Abbreviations which are used throughout these schemes and in the application generally, are identified in the following table:
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Example 1 - Synthesis
Scheme I
OH OTBS
Figure imgf000016_0001
4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l,2-dicarboxylic acid 1 -benzyl ester (2): A solution of Z-Hyp-OH (1, 300 g, 1.13 mol), TEA (395 mL, 2.83 mol), and DBU (17.2 g, 1.13 mol) in DMF (1.25 L) was stirred in a cold water bath while a suspension of TBS-Cl (188 g, 1.24 mol) in DMF (270 mL) was added slowly at 21-26 0C [Note: moderately exothermic]. The resulting thin suspension was stirred for 22 h at ambient temperature. The reaction mixture was cooled to 2 °C and quenched with water (1.54 L) at < 26 0C [Note: the pH of the aqueous layer was 8.5-9.0]. MTBE (3 L) was added and the mixture was acidified to pH 3-4 with cone. HCl (168 g) at 17-19 0C. The organic layer was separated and washed with water (2 x 1.5 L). The organic layer was concentrated in vacuo and dried by additional MTBE distillation. Toluene (2 x 500 mL) was added and distilled to remove moisture to provide 603 g of 2 as a light yellow-colored oil [Note: the water content by KF analysis was 508 ppm]. Based on drying a small sample of 2 to a solid, the contained weight of 2 was 412 g (96% yield, not corrected for purity). 1H NMR (300 MHz, CDCl3): δ7.34 (m, 3H), 7.29 (m, 2H), 5.24-5.11 (m, 2H), 4.52 (m, IH), 4.43 (m, IH), 3.64-3.42 (m, 2H), 2.27-2.09 (m, 2H), 0.85 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H) ppm; 13C NMR (75 MHz, J6-DMSO), mixture of rotomers: 5178.7, 178.4, 159.3, 158.9, 141.9, 141.8, 133.4, 133.3, 132.8, 132.6, 132.3, 131.9, 75.3, 74.6, 71.0, 71.0, 62.8, 62.3, 60.1, 59.7, 44.4, 43.4, 30.6, 30.6, 22.6, 22.6, 0.1, 0.0 ppm. Mass spectrum (ESI), m/z 379.5 [(M)+; calcd for C19H29NO5Si: 379.5].
Scheme II
Figure imgf000016_0002
2 3
4-(tert-Butyl-dimethyl-silanyloxy)-2-(6-flυoro-lH-indole-3-carbonyl)-pyrrolidine-l- carboxylic acid benzyl ester (3): Z-Hyp(OTBS)-OH (2, 55.5 g, 145 mmol) was dissolved in toluene (265 mL). DMF (0.1 mL) and oxalyl chloride (22.4 g, 174 mmol) were added at ambient temperature. After 2-3 h, the bubbling stopped. After 4 h, the mixture was concentrated in vacuo (65 0C bath, ca. 30 min) to provide 95 g of a light yellow-colored solution which was confirmed to be acid chloride by 1H NMR analysis.
6-Fluoroindole (39.2 g, 290 mmol) was dissolved in anhydrous chlorobenzene (300 niL) and toluene (200 mL) and the solution was cooled to -4 0C using an ice/acetone bath. A solution of 3M EtMgBr in diethyl ether (101 g, 294 mmol) was added over 31 minutes at <2.5 0C resulting in a pale amber-colored solution. After 30 min, the acid chloride/toluene solution (vide supra) was added over 45 minutes at <2 0C. The reaction mixture was kept cold for 1 h then allowed to slowly warm. After ca. 4 h (10.6 0C), the reaction mixture was quenched with glacial HOAc (9.0 g, exothermic to 17.5 0C) and then water (exothermic). Water (200 mL) and EtOAc (300 mL) were added and the organic layer was separated and washed with water (100 mL, slow separation). The organic layer was concentrated in vacuo to afford 227 g of 3 as an amber-colored oil which was used without further purification. 1H NMR (300 MHz, CDCl3), -2:1 mixture of rotomers: δ9.38 (m, 0.7H), 8.58 (m, 0.3H), 8.35 (app. dd, J = 5.2, 8.2 Hz, 0.3H), 8.03 (app. dd, J= 5.2, 8.2 Hz, 0.7H), 7.74 (d, J= 2.9 Hz, 0.7H), 7.66 (d, J = 2.9 Hz, 0.3H), 7.38-7.32 (m, 5H), 7.07 (m, IH), 6.95 (m, IH), 6.85 (m, IH), 5.26-4.92 (m, 3H), 4.54 (m, IH), 3.80 (app. dt, J= 5.2, 11.1 Hz, IH), 3.61 (app. d, J= 11.1 Hz, 0.3H), 3.55 (app. d, J = 11.1 Hz, 0.7H), 2.25-2.07 (m, 2H), 0.88 (s, 9H), 0.06 (s, 3H), 0.00 (s, 3H) ppm; 13C NMR (75 MHz, J6-DMSO), mixture of rotomers: 5193.4, 193.0, 159.3 (d, JCF = 235.5 Hz), 153.9 (d, JCF = 16.2 Hz), 136.7, 136.8 (d, JCF = 34.0 Hz), 134.6, 128.3, 127.8, 127.2, 126.6, 122.4, 113.7 (d, JCF = 13.5 Hz), 110.2 (d, JCF = 20.2 Hz), 98.5 (d, JCF = 25.4 Hz), 70.6, 69.8, 65.8, 65.8, 60.6, 60.3, 55.5, 55.0, 25.7, 25.6, 17.7, 17.7, -4.8, -4.9 ppm. Mass spectrum (ESI), m/z 518.9 [[(M-H)+Na]+; calcd for C27H32FN2O4SiNa: 518.6].
Scheme III
Figure imgf000017_0001
3 4
2-(6-Fluoro-lH-indole-3-carbonyl)-4-hydroxy-pyrrolidine-l-carboxyhc acid benzyl ester (4): To a solution containing 3 (227 g) in THF (600 mL) was added 1 M TBAF in THF (160 mL) at ambient temperature. After 9 h, another 20 mL of the 1 M TBAF/THF solution was added. After ca. 48 h, the reaction mixture was concentrated in vacuo and then redissolved in EtOAc (600 mL). The organic solution was washed with water (310 mL) and the product precipitated to form a thick suspension which was filtered (slow). The solids were washed with EtOAc (165 mL in portions) and dried to provide 43 g of 4. The combined filtrate was concentrated in vacuo to precipitate an additional 4.8 g of 4 after drying. 1H NMR (300 MHz, J6-DMSO), mixture of rotomers: 612.08 (br s, IH), 8.43 (d, J = 10.5 Hz, IH), 8.16 (ddd, J = 5.4, 8.7, 14.1 Hz, IH), 7.36-7.31 (m, 2H), 7.27 (app. d, J= 10.2 Hz, IH), 7.09-6.93 (m, 4H), 5.24 (dt, J = 8.1, 15.6 Hz, IH), 5.14 (br s, IH), 5.04 (app. d, J = 6.4 Hz, IH), 4.90 (app. dd, J = 13.4, 28.4 Hz, IH), 4.30 (br s, IH), 3.58-3.43 (m, 2H), 2.27 (m, IH)3 1.93 (m, IH) ppm; 13C NMR (75 MHz, J6-DMSO), mixture of rotomers: 5194.0, 193.6, 159.9 (d, JCf = 235.2 Hz), 154.6 (d, JCF = 9.6 Hz), 138.1. 137.5 (d, JCF = 26.9 Hz), 136.0, 129.0, 128.5, 128.1 (d, JCF = 40.0 Hz), 123.4, 123.3, 123.0, 122.9, 114.4 (d, JCF = 11.7 Hz), 110.6 (d, JCF = 23.7 Hz), 99.3 (d, JCF = 25.2 Hz), 69.5, 68.8, 66.4, 66.3, 61.4, 61.1, 56.2, 55.7 ppm. Mass spectrum (ESI), m/z 382.6 [(M)+; calcd for C2]H19FN2O4: 382.3].
Scheme IV
Ph3P
Figure imgf000018_0001
Figure imgf000018_0002
2-(6-Fluoro-lH-indole-3-carbonyl)-4-(4-nitro-benzoyloxy)-pyrrolidine-l-carboxylic acid benzyl ester (5): A solution containing 4 (51.1 g, 134 mmol), 4-nitrobenzoic acid (27.9 g, 167 mmol) and triphenylphosphine (48.9 g, 187 mmol) in anhydrous THF (700 mL) and DMF (175 mL) was cooled to 2 0C. DIAD (37.4 mL, 194 mmol) was added over 1 h at 2-3 0C. After 1 h, the solution was allowed to warm to ambient temperature. After ca. 16 h, the reaction mixture was concentrated in vacuo and MeOH (250 mL) was added and concentrated to form a thick suspension (322 g). Additional MeOH (250 mL) was added and the solution was concentrated in vacuo to afford a thick suspension (420 g) that was chilled in an ice bath. After ca. 1.5 h, the solid was collected on a vacuum filter and washed with chilled MeOH (190 mL). The product was air-dried on the filter to provide 82.9 g (>100%) of 5 as a light yellow-colored solid which was used directly in the next reaction. 1H NMR (300 MHz, J6-DMSO), mixture of rotomers: 512.14 (br s, IH), 8.47 (app. d, J = 6.6 Hz, IH), 8.29-8.21 (m, 3H), 8.03 (dd, J = 2.7, 8.4 Hz, 2H), 7.43-7.33 (m, 2H), 7.28 (app. dd, J = 2.1, 9.6 Hz, IH), 7.20-7.08 (m, 4H), 5.55 (br s, IH), 5.42 (dd, J= 8.4, 15.3 Hz, IH), 5.13 (dd, J = 12.6, 22.2 Hz, IH), 5.04 (s, IH), 3.99 (m, IH), 3.73 (d, J= 12.3 Hz, IH), 2.91 (m, I H), 2.36 (m, IH) ppm; 13C NMR (75 MHz, J6-DMSO), mixture of rotomers: 5192.9, 192.4, 164.2, 160.0 (d, JCF = 235.5 Hz), 154.5 (d, JCF = 12.0 Hz), 150.9, 137.5, 137.1 (d, JCF = 12.6 Hz), 135.6, 135.1, 131.3, 128.9 (d, JCF = 28.0 Hz), 128.5, 128.2, 128.1, 127.6, 124.2, 123.0, 113.5 (d, JCF = 8.5 Hz), 110.9 (d, JCF = 21.9 Hz), 99.1 (d, JCF = 25.5 Hz), 75.2, 74.3, 66.7, 66.5, 62.4, 62.1, 53.6, 53.0, 38.6, 37.6 ppm. Mass spectrum (ESI), m/z 531.8 [(M)+; calcd for C28H22FN3O7: 531.5].
Scheme V
Figure imgf000019_0001
2-(6-Fiuoro-lH-indole-3-carbony1i)-4-hydiOxy-ρyrrolidine-l-carboxyiic acid benzyl ester (6): To a suspension of 5 (82.9 g) in THF (600 mL), MeOH (200 mL), and water (100 mL) was added 50% aq. NaOH (16.0 g, 200 mmol) [Note: exothermic; temp, increase: 23.7 0C to 25.9 0C]. After 2 h, glacial HOAc (5.3 g) was added to adjust the pH to 7-8 [Note: the orange- colored solution changed to pale yellow] and the reaction mixture was concentrated in vacuo. Water (500 mL) was added and solvent was removed in vacuo until a thick suspension formed. The solid was collected on a vacuum filter and washed with water (400 mL in portions). The solid was dried in a vacuum oven at 55 0C to afford 42.6 g (83%, 2 steps) of 6 as an off-white solid. 1H NMR (300 MHz, J6-DMSO): 58.38 (d, J= 11.1 Hz, IH), 8.14 (ddd, J = 5.7, 8.7, 14.1 Hz, IH), 7.35-7.29 (m, 2H), 7.25 (app. dd, J = 2.1, 9.9 Hz, IH), 7.10-6.95 (m, 4H), 5.16-4.98 (m, 2H), 4.90 (app. q, J = 13.5, 25.8 Hz, IH), 4.26 (m, IH), 3.74 (app. ddd, J = 6.3, 11.1, 18.3 Hz, IH), 3.22 (m, IH), 2.59 (m, IH), 1.73 (app. ddd, J = 6.6, 12.9, 25.2 Hz, IH) ppm; 13C NMR (75 MHz, J6-DMSO): 5193.8, 193.3, 160.0 (d, JCF = 235.2 Hz), 154.4 (d, JCF = 14.5 Hz), 137.5 (d, JCF = 26.0 Hz), 137.2 (d, JCF = 12.3 Hz), 129.0, 128.5, 128.2 (d, JCF = 35.4 Hz), 128.1, 127.4, 123.2, 123.1, 114.4 (d, JCF = 11.4 Hz), 1 10.8 (d, JCF = 23.7 Hz), 110.8 (d, JCF = 23.7 Hz), 99.0 (d, JCF = 25.8 Hz), 69.4, 68.6, 66.5, 66.4, 61.5, 61.2, 54.9, 54.6 ppm. Mass spectrum (ESI), m/z 383.8 [(M+H)+; calcd for C2 IH20FN2O4: 383.3]. Scheme VI
Figure imgf000020_0001
2-(6-Fluoro-lH-indol-3-ylmethyl)-4-hydroxy-pyrrolidine-l-carboxylic acid benzyl ester (7): To a suspension of 6 (10.1 g, 26 mmol) in anhydrous THF (200 mL) was added 2M LiBH4 in THF (26.2 mL, 52 mmol) over ca. 7 min [Note: exothermic; temp, increase: 21.5 0C to 28.2 0C]. After 2.5 h, the pale, yellow-colored solution was cooled to ca. 11 °C and methanesulfonic acid (4.66 g, 48 mmol) was added over ca. 4 min [Note: exothermic; temp, increase to 14.2 0C].
After 16 h, the reaction mixture was cooled in an ice-bath and carefully quenched with water (50 mL) [Note: the addition of water was exothermic and released a large quantity of gas]. Following the addition of water, the pH was adjusted to 1 with cone. HCl (1.9 g). The reaction mixture was concentrated to remove THF and the aqueous solution was extracted with EtOAc (110 mL). The organic layer was separated and washed with water (2 x 50 mL) [Note: final pH about 5]. The organic solution was concentrated in vacuo and azeotropically dried using anhydrous EtOAc to provide 10.2 g of 7 as a white foam [Note: 87.7 A% by HPLC analysis]. 1H NMR (300 MHz, J6-DMSO), -1 :1 mixture of rotomers: 810.91 (app. d, J = 5.4 Hz, IH), 7.69 (dd, J = 6.0, 8.4 Hz, 0.5H), 7.48-7.30 (m, 4.5H), 7.13- 7.07 (m, 3H), 6.85 (app. t, J = 8.4 Hz, 0.5H), 6.58 (app. t, J = 9.9 Hz, 0.5H), 5.19-5.10 (m, 3H), 4.25 (br s, IH), 4.03-3.96 (m, IH), 3.55 (dd, J= 5.1, 11.4 Hz, IH), 3.29 (d, J = 11.4 Hz, IH), 3.17-2.98 (m, 2H), 1.79 (m, 2H) ppm. 13C NMR (300 MHz, c^-DMSO), mixture of rotomers: δl59.5 (d, JCF = 232.1 Hz), 159.4 (d, JCF = 232.3 Hz), 154.9, 137.7 (d, JCF = 36.6 Hz), 136.7 (d, JCF = 12.6 Hz), 136.6 (d, JCF = 12.9 Hz), 129.1, 129.1, 128.7, 128.6 (d, JCF = 26.3 Hz), 128.2, 125.0 (d, JCF = 21.4 Hz), 124.5, 124.3, 120.1 (d, JCF = 28.3 Hz), 120.0 (d, JCF = 28.6 Hz), 112.4 (d, JCF = 14.6 Hz), 107.4 (d, JCF = 24.3 Hz), 107.3 (d, JCF = 24.3 Hz), 69.9, 69.2, 67.1, 66.3, 58.7, 58.1, 56.1, 55.6, 38.3, 37.6, 31.2, 30.1 ppm. Mass spectrum (ESI), m/z 368.6 [(M)+; calcd for C2iH2iFN2O3: 368.4]. Scheme VII
Figure imgf000021_0001
4-Acetoxy-2-(6-fluoro-lH-indol-3-ylmethyl)-pyrrolidine-l-carboxylic acid benzyl ester (8): To a solution containing 7 (4.7 g, 12.8 mmol) and DMAP (81 mg, 0.66 mmol) in DCM (100 mL) was added acetic anhydride (2.6 g, 25.5 mmol) at ambient temperature. After 16 h, the reaction mixture was quenched with a MeOH (ca. 3 mL) and washed successively with 10% aq. Na2CO3 (50 mL), dilute HCl (50 mL), and 10% aq. Na2CO3 (50 mL). The organic solution was concentrated in vacuo and filtered through a short column of silica gel (ca. 25 g) [eluant: DCM (200 mL) to 0.5% (v/v) MeOH/DCM (80 mL) to 2% MeOH/DCM (100 mL) to 5% MeOH/DCM (100 mL)]. The product-containing fractions were combined and concentrated to provide 3.28 g (63%) of 8 as a white foam [Note: 94.3 A% by HPLC analysis]. 1H NMR (300 MHz, CDCl3), -1:1 mixture of rotomers: 57.99 (m, IH), 7.75-6.61 (m, 9H), 5.28 (m, IH), 5.20 (m, 2H), 4.23 (m, IH), 3.82 (dt, J= 5.4, 13.5 Hz, IH), 3.60 (app. t, J= 13.2 Hz, IH), 3.50 (d, J= 11.7 Hz, 0.5H), 3.31 (d, J= 12.9 Hz, 0.5H), 2.87 (dt, J= 5.1, 13.5 Hz, IH), 2.13 (s, 3H), 2.01 (m, 2H) ppm; 13C NMR (75 MHz, CDCl3), -1 :1 mixture of rotomers: 5170.8, 160.2 (JCF = 236.4 Hz), 155.2, 136.8, 136.6, 136.4, 128.9, 128.8, 128.5 (JCF = 24.3 Hz), 124.5 (JCF = 21.4 Hz), 123.0, 123.0, 120.0 (JCF = 27.1 Hz), 119.9 (JCF = 26.0 Hz), 112.8 (JCP = 10.5 Hz), 108.2 (JCF = 24.3 Hz), 97.7 (JCF = 25.7 Hz), 74.0, 73.2, 67.9, 67.2, 58.5, 57.6, 53.4, 53.0, 35.4, 34.6, 30.8, 29.7, 21.5 ppm. Mass spectrum (ESI), m/z 410.6 [(M)+; calcd for C23H23FN2O4: 410.4].
Scheme VIII
Figure imgf000021_0002
4-Acetoxy-2-[3'-(4-acetoxy-l -benzyloxycarbonyl-pyrrolidin-2-ylmethyl)-6,6'-difluoro- lH,rH-[2,2']biindolyl-3-ylmethyl]-pyrrolidine-l-carboxylic acid benzyl ester (9): A solution containing 8 (2.9 g, 7.1 mmol) in EtOAc (ca. 5 mL) was cooled in an ice-bath and pre-cooled TFA (20.3 mL) was added in one portion. The resulting yellow-colored solution was stirred at 2-4 0C. After 4.75 h, the cold reaction mixture was transferred (via canula) with stirring into a pre-cooled mixture of EtOAc (30 mL), and 25% aq. K2CO3 (80.7 g). The aqueous layer was separated and extracted with EtOAc (3 x 30 mL) and the combined organic extracts were washed with 10% aq. Na2CO3 (30 g). The organic solution was concentrated in vacuo and azeotropically dried using anhydrous EtOAc to afford 2.95 g of indolylindoline diastereomers as a yellow-colored foam which was used directly in the next reaction. Mass spectrum (ESI), m/z 821.3 [(M)+; calcd for C46H46F2N4O8: 820.9].
To a solution containing the indolylindoline diastereomers (2.95 g) in EtOAc (30 mL) was added DDQ (885 mg, 3.9 mmol) in one portion [Note: exothermic; temp, increase: 26 0C to 31.6 0C]. After 3 h, the dark orange/brown-colored reaction mixture was filtered through Celite® which was subsequently rinsed with EtOAc (50 mL). [Note: a second reaction performed at 0.5 mmol-scale was combined for work-up]. The filtrate was washed with 10% aq. Na2CO3 (2 washes: 74 g, then 58 g). The organic layer was concentrated in vacuo to provide 2.14 g of 9 as a light brown-colored solid.
The Celite® pad was further rinsed with THF (100 mL) which was concentrated in vacuo to provide another 1.12 g of 9 as a beige-colored solid. The combined solids were dissolved in isopropyl acetate (iPrAc, 50 mL). The iPrAc solution was reduced to ca. 20 mL and resulting suspension was warmed to reflux, cooled to ambient temperature, and then placed in an ice-bath. After 1 h, the solid was collected by vacuum filtration, washed with iPrAc (10 mL) and dried in a vacuum oven to afford 2.13 g (65%, 2 steps) of 9 as a beige- colored solid [Note: -100 A% by HPLC analysis]. 1H NMR (300 MHz, CDCl3): δl 1.29 (br s, 2H), 7.57-7.36 (m, 14H), 6.90 (app. dt, J = 2.1, 9.3 Hz, 2H), 5.39-5.30 (m, 6H), 4.28 (t, J = 9.0 Hz, 2H), 3.84-3.73 (m, 4H), 3.66 (d, J = 13.2 Hz, 2H), 3.40 (dd, J = 12.0, 14.4 Hz, 2H), 2.31 (s, 6H), 2.17 (m, 2H), 2.05 (m, 2H) ppm; 13C NMR (75 MHz, CDCl3): 5170.7, 161.9, 158.8, 156.3, 137.5, 137.3, 136.5, 128.9, 128.6, 128.5, 125.9, 118.8, 118.6, 108.8, 108.5, 108.3, 98.7, 98.3, 74.4, 68.0, 60.1, 53.5, 34.5, 28.9, 21.7 ppm. Mass spectrum (ESI), m/z 818.2 [(M)+; calcd for C46H44F2N4O8: 818.8]. Scheme IX
Figure imgf000023_0001
Acetic acid 5-[3'-f4-acetoxy-pyrrolidm-2-ylmethyl)-6,6'-difluoro-lHJ'H-r2,2'1biindolyl-3- ylmethyl]-pyrrolidin-3-yl ester ClO): A suspension containing 9 (35 g, 42.7 mmol) in 1 :1 EtOAc/MeOH (400 mL) was distributed into two 500 mL Parr bottles (ca. 200 mL/each), and charged with 10% Pd-on-C (wet, 5000 mg/each, Aldrich®). The reaction mixture was pressurized to 50 PSI H2 and shaken for 3 h. The reaction mixture was filtered through a pad of Celite® and the solids were washed with EtOAc. The clarified filtrate was concentrated in vacuo to afford 24 g of 10 as an off-white solid which was used directly in the next reaction. 1H NMR (300 MHz, CDCl3): 513.10 (br s, 2H) 7.45 (dd, J = 5.2, 8.9 Hz, 2H), 7.03 (dd, J = 2.3, 9.8 Hz, 2H), 6.85 (m, 2H), 5.35 (m, 2H), 3.71 (m, 2H), 3.18-3.35 (m, 4H), 2.90-3.14 (m, 4H), 2.56 (m, 2H), 2.00-2.10 (m, 2H)3 2.04 (s, 6H), 1.80-1.92 (m, 2H) ppm; 13C NMR (75 MHz, CDCl3): 6171.3, 161.7, 158.6, 136.1, 135.9, 130.5, 130.4, 125.4, 119.1, 118.9, 109.6, 108.0, 107.6, 97.6, 97.5, 75.1, 57.7, 51.6, 38.7, 32.8, 21.6 ppm. Mass spectrum (ESI), m/z 550.9 [(M)+; calcd for C30H32F2N4O4: 550.6].
Scheme X
Figure imgf000023_0002
Acetic acid 5- {3'-[4-acetoxy-l -(2-tert-butoxycarbonylamino-butyryl)-pyrrolidin-2-ylmethyl]- 6,6l-difluoro-lHJ'H-[2,2'lbiindolyl-3-ylmethyl}-l-(2-tert-butoxycarbonylamino-butyryl)- pyrrolidin-3-yl ester (11): To a solution containing Boc-Abu-OH (20.4 g, 100 mmol) and HATU (42.0 g, 1 10 mmol) in anhydrous NMP (150 mL) at 0 0C was added NMM (16 mL, 150 mmol) followed by a solution of 10 (24 g, 42 mmol) in NMP (100 mL). The reaction mixture was slowly warmed to ambient temperature. After 16 h, the reaction mixture was diluted with MTBE (1000 mL) and the heterogeneous mixture was washed with water (500 mL). The layers were separated and the organic phase formed a heterogeneous suspension. MTBE (1000 mL) and EtOAc (500 mL) were added and the now-homogeneous solution was washed successively with 1 N HCl (2 x 100 mL), saturated aqueous NaHCO3 (2 x 100 mL), brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was dissolved in 1 :1 DCM/ MeOH (600 mL) and DCM (ca. 200 mL) was removed via distillation at 50 0C [Note: a small quantity of white precipitate was observed]. MeOH (200 mL) was added and additional solvent was removed (ca. 200 mL) at 50 0C. The heterogeneous mixture was cooled at -5 0C. After 16 h, the solid was collected by vacuum filtration and washed with cold MeOH. The solid was dried under high vacuum to afford 32 g of 11 as an off-white solid. 1H NMR (300 MHz, CDCl3), mixture of rotomers: δ 11.22 (br s, 2H), 7.40 (dd, J = 5.1, 8.7 Hz, 2H), 7.31 (d, J = 9.3 Hz, 2H), 6.76 (dd, J - 8.40, 8.40, 2H) 6.26 (br s, 2H), 5.44 (m, 2H), 4.39 (dd, J = 7.5, 16.5 Hz, 2H), 4.24 (m, 2H), 4.15 (dd, J = 5.1, 12.9 Hz, 2H), 3.79 (d, J = 12.9 Hz, 2H), 3.10-3.30 (m, 4H), 2.32 (d, J= 14.7 Hz, 2H), 2.24 (s, 6H), 1.90 (m, 2H), 1.74 (m, 2H), 1.56 (s, 18H), 0.99 (t, J = 7.5 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): 5172.2, 170.4, 161.4, 158.3, 155.8, 137.0, 136.9, 128.6, 125.5, 118.9, 118.7, 108.6, 108.4, 108.1, 98.3, 98.0, 80.8, 74.7, 60.4, 53.8, 53.5, 34.1, 28.7, 28.6, 26.2, 21.5, 10.5 ppm. Mass spectrum (ESI), m/z 920.5 [(M)+; calcd for C48H62F2N6Oi0: 921.0].
Scheme XI
Figure imgf000024_0001
Acetic acid 5-{3'-[4-acetoxy-l-(2-amino-butyryl)-pyrrolidin-2-ylmethyl]-6,6'-difluoro- lHJ'H-r2,2']bimdolyl-3-ylmethyl)-l-(2-amino-butyryl)-pyrrolidin-3-yl ester (12): A solution containing 11 (27.5 g, 30 mmol) in DCM (200 mL) was cooled to 0 0C. TFA (50 mL) was added and the reaction was monitored by LC/MS analysis until complete conversion of 11 to 12 (ca. 3 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (ca. 1 L). The EtOAc solution was carefully poured into a saturated aqueous NaHCO3/ice/water mixture to neutralize the residual TFA. The organic phase was separated and washed twice with saturated aqueous NaHCO3 then once with brine. The combined aqueous washes were back-extracted with EtOAc (2 x 100 mL) and the combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated to afford 22 g of crude 12 as an off-white solid. 1H NMR (300 MHz, CDCl3 + J4-MeOH), mixture of rotomers: δl l.62 (br s, 2H), 7.48-7.62 (m, 4H), 6.89 (ddd, J= 2.4, 9.3, 9.3 Hz, 2H), 5.48 (dd, J= 4.5, 4.8 Hz, 2H), 4.52 (dd, J= 9.3, 9.3 Hz, 2H), 4.06 (dd, J= 4.8, 12.3 Hz, 2H), 3.78 (d, J = 12.3 Hz, 2H), 3.54-3.70 (m, 4H), 3.30-3.40 (m, 2H), 2.33 (s, 6H), 2.02-2.16 (m, 2H), 1.70- 1.96 (m, 4H), 1.09 (t, J= 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3 + J4-MeOH): 5173.5, 170.9, 161.8, 158.6, 137.2, 137.1, 128.2, 128.1, 125.6, 118.7, 118.6, 108.6, 108.3, 108.0, 98.6, 98.1, 74.6, 60.1, 53.5, 33.5, 28.0, 21.4, 9.7 ppm. Mass spectrum (ESI), m/z 721.4 [(M)+; calcd for C38H46F2N6O6: 720.8].
Scheme XII
Figure imgf000025_0001
Acetic acid 5-(3'-{4-acetoxy-l-[2-(2-methyl-(tert-butoxycarbonylVamino-propionylamino)- butyryl1-pyrrolidin-2-ylmethvU-6,6'-difluoro-lHJΗ-[2,2'lbiindolyl-3-ylmethyl)-l-r2-(2- methyl-(tert-butoxycarbonyl)-amino-propionylamino)-butyryl]-pyrrolidin-3-yl ester (13): To a solution containing BoC-N(Me)AIa-OH (14.6 g, 72 mmol) and HATU (30.4 g, 80 mmol) in anhydrous NMP (150 mL) at 0 0C was added NMM (12 mL, 105 mmol) followed by addition of 12 (30 mmol) in NMP (200 mL). The resulting mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (1 L) and washed successively with water (1 L), IN HCl (2 x 100 mL), saturated aqueous NaHCO3 (2 x 100 mL), brine, dried over anhydrous Na2SO4, filtered, concentrated to afford 33.5 g of crude 13.
The crude 13 was dissolved in EtOH (50 mL) and then slowly added to water (1000 mL) with vigorous stirring at 50 0C which resulted in the precipitation of a white solid. The heterogeneous mixture was cooled to -5 0C. After 16 h, the solid was collected by vacuum filtration and washed with water. The wet solid was dried under high vacuum at 50 0C to afford 29.9 g of 13 as an off-white solid. 1H NMR (300 MHz, CDCl3): δl l.57 (br s, 2H), 7.40-7.60 (m, 4H), 6.89 (m, 2H), 5.50 (m, 2H), 4.75 (m, 2H), 4.67 (q, J = 6.9 Hz, 2H), 4.50 (t, J = 9.6 Hz, 2H), 4.20 (dd, J = 3.9, 12.3 Hz, 2H) 3.85 (d, J = 12.3 Hz, 2H), 3.57 (br d, J = 13.5 Hz, 2H), 3.34 (dd, J = 12.0, 13.8 Hz, 2H), 2.89 (s, 6H), 2.34 (s, 6H), 2.10 (m, 2H), 1.95 (dt, J= 6.0, 13.8 Hz, 2H), 1.79 (dt, J = 7.2, 14.1 Hz, 2H), 1.52 (s, 18H), 1.39 (d, J = 7.2 Hz, 6H), 1.03 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): δ 174.0, 172.1, 171.9, 170.5, 161.8, 158.7, 137.5, 137.3, 128.4, 125.8, 118.7, 118.6, 108.8, 108.4, 108.1, 98.8, 98.5, 81.0, 74.6, 60.1, 54.0, 52.0, 33.7, 30.5, 28.6, 28.1, 25.9, 21.6, 14.0, 9.9 ppm. Mass spectrum (ESI), m/z 1091.7 [(M)+; calcd for C56H76F2N8Oi0: 1091.2].
Scheme XIII
Figure imgf000026_0001
Acetic acid 5-(3'- {4-acetoxy- 1 -[2-(2-methylammo-propionylamino)-butyryl] -pyrrolidin-2- ylmethvU-6.6'-difluoro-lH.l'H-[2.2'1biindolyl-3-ylmethyl)-l-r2-(2-methylamino- propionylamino)-butyryl]-pyrrolidin-3-yl ester (14): A solution containing 13 (28.5 g, 26 mmol) in DCM (150 mL) was cooled to 0 0C. TFA (50 mL) was added. After 30 min, the reaction mixture was warmed to ambient temperature and monitored until LC/MS analysis revealed complete conversion of 13 to 14 (ca. 4 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (500 mL) and carefully poured onto an aqueous NaHCO3/ice mixture. The aqueous phase was separated and back-extracted with EtOAc (2 x 250 mL). The combined organic extracts were washed several times with saturated aqueous NaHCO3, then brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford 24 g of 14 as a light yellow-colored solid. 1H NMR (300 MHz, CDCl3): δl 1.66 (br s, 2H), 8.16 (d, J= 8.4 Hz, 2H), 7.52 (dd, J= 2.1, 9.6 Hz, 2H), 7.43 (dd, J = 5.4, 8.4 Hz, 2H), 6.83 (ddd, J = 2.1, 9.0, 9.0 Hz, 2H), 5.41 (dd, J = 4.2, 4.5 Hz, 2H), 4.64 (dd, J = 7.8, 14.1 Hz, 2H), 4.36 (br d, J = 9.3, 9.6 Hz, 2H), 4.13 (dd, J - 4.8, 12.6 Hz, 2H), 3.81 (d, J = 12.0 Hz, 2H), 3.44 (d, J = 13.2 Hz, 2H), 3.0-3.18 (m, 4H), 2.50 (s, 6H), 2.30 (s, 6H), 2.15 (d, J = 14.4 Hz, 2H), 1.90-2.08 (m, 2H), 1.76-1.90 (m, 2H), 1.33 (d, J = 7.2 Hz, 6H), 1.08 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3): 5175.3, 172.6, 170.4, 161.8, 137.5, 137.3, 128.4, 128.3, 125.9, 1 18.6, 118.5, 108.5, 108.1, 107.8, 98.7, 98.3, 74.5, 60.9, 59.9, 53.9, 51.3, 35.8, 33.6, 27.6, 26.2, 21.5, 20.2, 10.1 ppm. Mass spectrum (ESI), m/z 891.6 [(M)+; calcd for C46H60F2N8O8: 891.0],
Scheme XIV
Figure imgf000027_0001
N-(l S-r2R-(6.6'-Difluoro-3'-(4S-hvdroxy-l-r2S-(2S-methylamino-propionylamino)- butyryll-pyrrolidin-2R-ylmethyl|-lH.l'H-["2.2'lbiindolyl-3-ylmethyl)-4S-hvdroxy- pyrrolidine-l-carbonyl]-propyl|-2S-methylamino-propionamide (15): To a solution containing 14 (24 g) in MeOH (200 mL) was added 1 M NaOH (80 mL) at 0 0C. The reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (200 mL) and extracted with EtOAc (500 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 150 mL). The combined organic extracts were washed with brine and dried over anhydrous Na2SO4, filtered, and concentrated to afford 22.5 g of crude 15 as a light, brown/yellow-colored solid.
The crude 15 (22.5 g) was dissolved in McOH (50 mL) and EtOAc (200 mL). The volume was reduced (50%) by distillation at reduced pressure at 60 0C using a rotary evaporator. MTBE (300 mL) was added and the cloudy solution was warmed to 60 0C. After 30 min, the solution was cooled to ambient temperature and then maintained at -5 0C.
After 16 h, the solid was collected by vacuum filtration and washed with cold 25% EtOAc/MTBE and dried under high vacuum at ambient temperature to afford 16.6 g of 15 as an off-white solid. An additional 5.5 g of 15 was recovered from the filtrate via solvent removal and vacuum drying. 1H NMR (300 MHz, CDCl3): δl 1.74 (s, 2H), 8.27 (d, J = 8.7 Hz, 2H), 7.71 (dd, J= 5.4, 8.4 Hz, 2H), 7.55 (dd, J =2.4, 9.6 Hz, 2H), 6.88 (ddd, J= 2.4, 9.3, 9.3 Hz, 2H), 4.62-4.78 (m, 4H), 4.43 (dd, J = 9.3, 9.9 Hz, 2H), 4.03 (dd, J = 4.8, 11.4 Hz, 2H), 3.80 (d, J = 11.4 Hz, 2H), 3.66 (dd, J = 2.7, 14.4 Hz, 2H), 3.53 (dd, J = 11.4, 14.4 Hz, 2H), 3.11 (q, J= 6.9 Hz, 2H), 2.56 (s, 6H), 2.45 (m, 2H), 2.19 (d, J= 14.4 Hz, 2H), 1.76-2.10 (m, 6H), 1.59 (br s, 2H), 1.39 (d, J= 6.9 Hz, 6H), 1.22-1.38 (m, 2H), 1.07 (t, J= 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, ^6-DMSO): 5175.2, 172.8, 161.6, 158.5, 137.3, 137.2, 128.4, 128.3, 126.4, 120.8, 120.6, 109.4, 108.7, 108.4, 98.4, 98.0, 70.8, 60.2, 59.9, 56.6, 51.8, 36.4, 35.3, 28.3, 25.6, 20.0, 10.6 ppm. Mass spectrum (ESI), m/z 807.5 [(M)+; calcd for C42H56F2N8O6: 806.9].
Scheme XV
Figure imgf000028_0001
ALfer/-butoxycarbonyl-./V-(d^-methyl)alanine (17): To a solution of Boc-Ala-OH (16, 3.5 g, 18.5 mmol) in anhydrous THF (50 mL) was added NaH (2.1 g, 60% in mineral oil, 51.0 mmol) at 0 0C. After 45 min, the reaction mixture was warmed to ambient temperature and then warmed to 45 0C for an additional 20 min. The reaction mixture was cooled to 0 0C and c/j-iodomethane (10.0 g, 69.0 mmol) was added. The resulting mixture was stirred at ambient temperature. After 16 h, the reaction mixture was quenched with water, and extracted with EtOAc. The organic phase was discarded and the aqueous solution was acidified to pH 3 with IN HCl and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 niL/min) to afford 17 (3.6 g, 94%) as a white solid following lyophilization. . 1H NMR (300 MHz, Ci4-MeOU), mixture of rotomers: δ4.80 (br s, IH), 4.67 (q, J= 6.9 Hz, 0.5H), 4.38 (q, J = 6.9 Hz, 0.5H), 1.36-1.52 (m, 12H) ppm; Mass spectrum (ESI), m/z 207.0 [(M+H)+; calcd for C9Hi5D3NO4: 207.2].
Scheme XVI
Figure imgf000028_0002
Acetic acid 5-(3'-{4-acetoxy-l-[2-(2-(ij-methyl-(tert-butoxycarbonyl)-amino- propionylamino)-bυtyryl]-pyrrolidin-2-ylmethyl}-6,6'-difluoro-lH,lΗ-[212']biindolyl-3- ylmethyl)-l-[2-f2-Jj-methyl-ftert-butoxycarbonyl)-amino-propionylamino)-butyryl]- pyrrolidin-3-yl ester (18): To a solution containing BoC-N(Ji-Me)AIa-OH (17, 1.00 g, 4.83 mmol) and HATU (2.00 g, 5.30 mmol) in anhydrous NMP (20 mL) at 0 0C was added NMM (0.8 mL, 7.20 mmol) followed by addition of 12 (crude, 1.73 g, 2.40 mmol) in NMP (20 mL). The resulting mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (200 mL) and washed successively with water (200 mL), IN HCl (2 x 100 mL), saturated aqueous NaHCO3 (2 x 100 mL), brine, dried over anhydrous Na2SO4, filtered, concentrated. The residue was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product-containing fractions were combined, frozen, and lyophilized to afford 1.1 g of 18 (42%) as an off-white solid. 1H NMR (300 MHz, CDCl3), mixture of rotomers: δl 1.56 (br s, 2H), 7.56 (dd, J= 5.4, 8.7 Hz, 2H), 7.52 (m, 2H), 7.10 (br s, 2H), 6.89 (ddd, J = 2.1, 9.0, 9.0 Hz, 2H), 5.47 (t, J = 4.8 Hz, 2H), 4.75 (br s, 2H), 4.67 (q, J= 6.9 Hz, 2H), 4.50 (t, J = 9.3 Hz, 2H), 4.18 (dd, J = 4.2, 11.7 Hz, 2H) 3.85 (d, J = 12.6 Hz, 2H), 3.57 (dd, J = 2.1, 14.4 Hz, 2H), 3.34 (dd, J = 12.0, 14.4 Hz, 2H), 2.34 (s, 6H), 2.29 (br s, 2H), 2.10 (m, 2H), 1.97 (m, 2H), 1.79 (m, 2H), 1.51 (s, 18H), 1.39 (d, J= 6.9 Hz, 6H), 1.03 (t, J= 7.5 Hz, 6H) ppm. Mass spectrum (ESI), m/z 1097.7 [(M)+; calcd for C56H70D6F2N8O12: 1097.3].
Scheme XVII
Figure imgf000029_0001
Acetic acid 5-(3'-{4-acetoxy-l-[2-(2-(j-methylamino-propionylamino)-buryryl]-pyrrolidin-2- ylmethyl)-6,6'-difluoro-lH.lΗ-r2,2'lbiindolyl-3-ylmethylVl-[2-(2-άfrmethylamino- propionylamino)-butyryl]-pyrrolidin-3-yl ester (19): A solution containing 18 (1.10 g, 1.00 mmol) in DCM (15 mL) was cooled to 0 0C. TFA (5 mL) was added. After 30 min, the reaction mixture was warmed to ambient temperature and monitored until LC/MS analysis revealed complete conversion of 18 to 19 (ca. 4 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (100 mL) and carefully poured onto an aqueous NaHCO3/ice mixture. The aqueous phase was separated and back-extracted with EtOAc (2 x 50 niL). The combined organic extracts were washed several times with saturated aqueous NaHCO3, and then brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford crude 19 which was used without further purification. Mass spectrum (ESI), m/z 897.5 [(M)+; calcd for C46H54D6F2N8O8: 897.0].
Scheme XVIII
Figure imgf000030_0001
N- ( 1 S-r2R-(6.6'-Difluoro-3'- {4S-hvdroxy-l -[2S-( 2S-J1-methylamino-propionylamino')- butyryll-pyrrolidin-2R-ylmethvU-lHJ'H-r2,2'1biindolyl-3-ylmethvn-4S-hvdroxy- pyrrolidine-l-carbonyl]-propyU-2S-<i^-methylamino-propionamide (20): To a solution containing crude 19 (ca. 1.00 mmol) in MeOH (20 mL) was added 1 M NaOH (2 mL) at ambient temperature. After 35 min, the MeOH was removed in vacuo and the residue was diluted with water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine and dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product- containing fractions were combined, frozen, and lyophilized to afford 0.6 g of 20 (75%) as a flocculent, white solid. 1H NMR (300 MHz, CD3CN), mixture of rotomers: δ 11.86 (s, 2H), 7.91 (d, J = 7.8 Hz, 2H), 7.71 (dd, J = 5.4, 8.7 Hz, 2H), 7.45 (dd, J = 2.4, 9.9 Hz, 2H), 6.83 (m, 2H), 4.56 (m, 2H), 4.47 (m, 2H), 4.20 (m, 2H), 3.84 (dd, J= 4.2, 11.1 Hz, 2H), 3.66 (d, J = 11.1 Hz, 2H), 3.45 (m, 4H), 2.93 (q, J = 6.9 Hz, 2H), 1.60-1.89 (m, 8H), 1.19 (d, J = 6.9 Hz, 6H), 0.94 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CD3CN + ^-MeOH), mixture of rotomers: 5175.2, 173.0, 162.4, 159.3, 137.8, 137.6, 128.8, 128.7, 126.8, 110.8, 120.7, 109.5, 108.7, 108.4, 98.5, 98.1, 71.6, 60.5, 60.1, 56.8, 52.6, 36.6, 28.6, 26.0, 22.7, 19.0, 10.1 ppm. Mass spectrum (ESI), m/z 813.4 [(M)+; calcd for C42H50D6F2N8O6: 813.0].
Figure imgf000031_0001
2-(6-Fluoro-lH-indol-3-yl-iJ7-methyl)-4-hvdroxy-pyrrolidine-l-carboxylic acid benzyl ester (21): A suspension of 6 (3.0 g, 7.85 mmol) in anhydrous THF (50 niL) was cooled to 0 0C. J^-NaBH4 (0.66 g, 15.7 mmol) was added in one portion followed by the addition of BF3-etherate (1.1 mL, 8.60 mmol). After ca. 10 min, the ice bath was removed and the reaction mixture was warmed to reflux.
After 3 h, the reaction mixture was cooled in an ice-bath and carefully quenched with saturated aqueous NH4Cl (50 mL). The biphasic mixture was diluted with EtOAc and the organic layer was separated and washed with water (2 x 50 mL) then brine. The EtOAc layer was dried over anhydrous Na2SO4, filtered, and concentrated to afford 3.2 g of crude 21 (>quant.) which was used without further purification. Mass spectrum (ESI), m/z 371.2 [(M+H)+; calcd for C2]H20D2FN2O3: 371.4].
Scheme XX
Figure imgf000031_0002
21 22
4-Acetoxy-2-(6-fluoro-lH-indol-3-yl-(i;-methyl)-pyrrolidine-l-carboxylic acid benzyl ester (22): To a solution containing crude 21 (ca. 7.85 mmol), Et3N (1.2 g, 12.0 mmol), and DMAP (50 mg, cat.) in DCM (30 mL) was added acetic anhydride (0.74 mL, 7.85 mmol) at ambient temperature. After 3 h, the reaction mixture was quenched with saturated aqueous NaHCO3 (50 mL) then diluted with DCM. The DCM layer was separated and washed successively with dilute HCl (50 mL), water (50 mL), and brine (50 mL). The organic solution was dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by flash silica gel chromatography [30-40% EtOAc in hexane] to afford 2.0 g (62%, 2 steps) of 22 as a white foam. 1H NMR (300 MHz, CDCl3), -1 :1 mixture of rotomers: 58.41 (br s, IH), 7.80-6.50 (m, 9H), 5.25 (m, IH), 5.21 (m, 2H), 4.27 (m, IH), 3.82 (dt, J = 5.1 , 13.2 Hz, IH), 3.61 (dd, J = 1 1.4, 11.7 Hz, IH), 2.13 (s, 3H), 2.00 (m, 2H) ppm; 13C NMR (75 MHz, CDCl3), -1 :1 mixture of rotomers: 5170.8, 160.2 (JCF = 236.2 Hz), 155.2, 136.9, 136.6, 136.5, 129.0, 128.9, 128.6 (JCF = 24.4 Hz), 124.5 (JCF = 22.1 Hz), 123.1, 120.1 (JCF = 27.2 Hz), 1 19.9 (JCF = 27.2 Hz), 112.8, 108.2 (JCF = 23.5 Hz), 97.7 (JCF = 25.7 Hz), 74.1 , 73.3, 68.0, 67.2, 58.5, 57.6, 53.4, 53.1, 35.4, 34.6, 21.5 ppm. Mass spectrum (ESI), m/z 413.1 [(M)+; calcd for C23H2 IU2FN2O4: 412.4].
Scheme XXI
Figure imgf000032_0001
4-Acetoxy-2-[3'-(4-acetoxy-l-benzyloxycarbonyl-pyrrolidin-2-yl-J?-methyl)-6,6'-difluoro- lH,rH-[2,2']biindolyl-3-yl-^7-methyl]-pyrrolidine-l-carboxylic acid benzyl ester (23): Indole 22 (2.0 g, 4.80 mmol) was dissolved in pre-cooled (-5 0C) TFA (10 mL). The resulting yellow-colored solution was allowed to slowly warm to ambient temperature over 2 h. The reaction mixture was concentrated in vacuo to remove the TFA and the crude mixture of indolylindoline diastereomers was used directly in the next reaction. Mass spectrum (ESI), m/z 825.4 [(M)+; calcd for C46H42D4F2N4O8: 824.9].
To a solution containing the indolylindoline diastereomers in EtOAc (100 mL) was added DDQ (0.58 g, 2.5 mmol) in one portion. After 15 min, the dark orange/brown-colored reaction mixture was quenched with saturated aqueous NaHCO3. The layers were separated and the organic phase was washed successively with saturated aqueous NaHCO3 (3 x 50 mL) and brine, dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was dissolved in DCM (10 mL) and the solution was then diluted with MeOH (50 mL). Slow removal of the DCM in vacuo afforded a precipitate which was collected by vacuum filtration, washed with cold MeOH, and dried to provide 1.7 g of 23 (86%, 2 steps). 1H NMR (300 MHz, CDCl3): δl 1.30 (br s, 2H), 7.60-7.30 (m, 14H), 6.90 (app. dt, J = 2.4, 9.3 Hz, 2H), 5.40 (m, 2H), 5.36 (d, J = 3.6 Hz, 4H), 4.28 (d, J = 8.1 Hz, 2H), 3.79 (m, 4H), 2.31 (s, 6H), 2.06 (m, 4H) ppm; Mass spectrum (ESI), m/z 823.3 [(M)+; calcd for C46H40D4F2N4O8: 822.9]. Scheme XXII
Figure imgf000033_0001
Acetic acid 5-[3'-(4-acetoxy-pyrrolidin-2-yl-(j?-methyl)-6,6'-difluoro-lH,l 1H- [2,2'lbiindolyl-3-yl-φ-methyl]-pyrrolidin-3-yl ester (24): A suspension containing 23 (0.40 g, 0.48 mmol) in 1 :1 EtOAc/MeOH (40 rnL) was placed in a 500 mL Parr bottle and charged with 10% Pd-on-C (wet, ca. 200 mg). The reaction mixture was pressurized to 50 PSI H2 and shaken for 3 h. The reaction mixture was filtered through a pad of Celite® and the solids were washed with EtOAc. The clarified filtrate was concentrated in vacuo to afford crude 24 as an off-white solid which was used directly in the next reaction. Mass spectrum (ESI), m/z 555.2 [(M)+; calcd for C30H28D4F2N4O4: 554.6].
Scheme XXIII
Figure imgf000033_0002
Acetic acid 5- {3 '-[4-acetoxy- 1 -(2-tert-butoxycarbonylamino-butyryl)-pyrrolidin-2-yl-J7- methyl1-6,6'-difluoro-lHJΗ-[2,2Hbiindolyl-3-yl-J7-methyl}-l-(2-tert-butoxycarbonylamino- butyryl)-pyrrolidin-3-yl ester (25): To a solution containing Boc-Abu-OH (224 mg, 1.1 mmol) and HATU (442 mg, 1.2 mmol) in anhydrous NMP (10 mL) at 0 0C was added NMM (0.2 mL, 1.7 mmol) followed by a solution of 24 (0.48 mmol) in NMP (10 mL). The reaction mixture was slowly warmed to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (100 mL) and the mixture was washed successively with water (5 x 50 mL), IN HCl (50 mL), saturated aqueous NaHCO3 (50 mL), and brine, dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by reverse- phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product- containing fractions were combined, concentrated, and lyophilized to afford 310 mg of 25 (70%, 2 steps) as a flocculent white solid. 1H NMR (300 MHz, CDCl3), mixture of rotomers: 611.17 (br s, 2H), 7.39 (dd, J= 5.4, 8.4 Hz, 2H), 7.29 (d, J= 9.3 Hz, 2H), 6.75 (dd, J= 8.40, 8.40, 2H), 6.40 (br s, 2H), 5.44 (m, 2H), 4.40 (dd, J= 7.8, 16.5 Hz, 2H), 4.22 (d, J = 7.8 Hz, 2H), 4.15 (dd, J= 5.1, 12.9 Hz, 2H), 3.80 (d, J = 12.9 Hz, 2H), 2.23 (s, 6H), 1.90 (m, 2H), 1.74 (m, 2H), 1.57 (s, 18H), 0.99 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3), mixture of rotomers: 6172.1, 170.4, 161.4, 158.2, 155.8, 137.0, 136.9, 128.6, 125.5, 118.9, 118.8, 108.6, 108.4, 108.1, 98.3, 98.0, 80.8, 74.7, 60.3, 53.8, 53.6, 34.1 , 28.7, 28.6 (br), 26.2, 21.5, 10.5 ppm. Mass spectrum (ESI), m/z 925.4 [(M)+; calcd for C48H58D4F2N6O10: 925.0].
Scheme XXIV
Figure imgf000034_0001
Acetic acid 5-(3'-[4-acetoxy-l-(2-amino-butyryl)-pyrrolidin-2-yl-(ij-methyl1-6,6'-difluoro- IH.1 'H-["2.2'lbiindolyl-3-yl- ^-methyl) - 1 -(2-amino-butyrylVpyrrolidin-3-yl ester (26): A solution containing 25 (310 mg, 0.34 mmol) in DCM (20 mL) was cooled to 0 0C. TFA (5 mL) was added and the reaction was monitored by LC/MS analysis until complete conversion of 25 to 26 (ca. 3 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (50 mL). The EtOAc solution was carefully poured into a saturated aqueous NaHCO3/ice/water mixture to neutralize the residual TFA. The organic phase was separated and washed twice with saturated aqueous NaHCO3 then once with brine. The combined aqueous washes were back-extracted with EtOAc (2 x 20 mL) and the combined organic extracts were dried over anhydrous Na2SO4, filtered, and concentrated to afford crude 26 (250 mg) as an off-white solid. Mass spectrum (ESI), m/z 725.3 [(M)+; calcd for C38H42D4F2N5O6: 724.8]. Scheme XXV
Figure imgf000035_0001
Acetic acid 5 -(3'- {4-acetoxy-l -[2-(2-methyl-ftert-butoxycarbonyl)-amino-propionylamino)- butyryli-pyrrolidin-2-yl-^-methvU -6,6'-difluoro- 1 H.1 Η-[2,2'1biindolyl-3-yl- JrmethylVl - [2-(2-methyl-(tert-butoxycarbonyl)-amino-propionylamino)-butyryl1-pyrrolidin-3-yl ester (27): To a solution containing Boc-N(Me)Ala-OH (83 mg, 0.41 mmol) and HATU (172 mg, 0.45 mmol) in anhydrous NMP (5 mL) at 0 0C was added NMM (0.1 mL, 0.85 mmol) followed by addition of crude 26 (123 mg, 0.17 mmol) in NMP (5 mL). The resulting mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (100 mL) and washed successively with water (50 mL), IN HCl (2 x 50 mL), saturated aqueous NaHCO3 (2 x 50 mL), brine, dried over anhydrous Na2SO4, filtered, concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product-containing fractions were combined, concentrated, and lyophilized to afford 170 mg of 27 (91%, 2 steps) as a flocculent, off-white solid. 1H NMR (300 MHz, CDCl3), mixture of rotomers: δl 1.51 (br s, 2H), 7.40-7.60 (m, 4H), 6.86 (m, 2H), 5.46 (m, 2H), 4.74 (br s, 2H), 4.65 (q, J = 6.9 Hz, 2H), 4.45 (d, J- 8.7 Hz, 2H), 4.17 (dd, J- 4.8, 12.3 Hz, 2H) 3.82 (d, J = 12.3 Hz, 2H), 2.87 (s, 6H), 2.28 (s, 6H), 2.05 (m, 2H), 1.92 (m, 2H), 1.78 (m, 2H), 1.48 (s, 18H), 1.37 (d, J = 7.2 Hz, 6H), 1.01 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3), mixture of rotomers: 5173.3, 170.2, 170.1, 170.5, 168.6, 159.9, 135.5, 135.4, 126.5, 126.4, 123.8, 116.8, 116.7, 106.8, J06.4, 106.1, 96.8, 96.5, 79.1, 72.6, 57.9, 52.1, 50.1, 31.7, 28.5, 26.6, 25.5 (br), 23.9, 19.6, 19.0, 12.1, 8.0 ppm. Mass spectrum (ESI), m/z 1095.5 [(M)+; calcd for C56H72D4F2N8Oi2: 1095.3]. Scheme XXVl
Figure imgf000036_0001
Acetic acid 5-(3'- {4-acetoxy-l -[2-(2-methylamino-propionylamino)-butyryl]-pyrrolidin-2-yl- ^2-methyll-6.6'-difluoro-lHJ'H-[2.2'lbiindolyl-3-yl-JrmethylVl-r2-(2-methylamino- propionylamino)-butyryl]-pyrrolidm-3-yl ester (28): A solution containing 27 (170 mg, 0.15 mmol) in DCM (15 mL) was cooled to 0 0C. TFA (5 mL) was added. After 30 min, the reaction mixture was warmed to ambient temperature and monitored until LC/MS analysis revealed complete conversion of 27 to 28 (ca. 4 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (100 mL) and carefully poured onto an aqueous NaHCO3/ice mixture. The aqueous phase was separated and back-extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed several times with saturated aqueous NaHCO3, then brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford crude 28 as a light yellow-colored solid. Mass spectrum (ESI), m/z 895.3 [(M)+; calcd for C46H56D4F2N8O8: 895.0],
Scheme XXVII
Figure imgf000036_0002
N- { lS-[2iM6,6'-Difluoro-3'- {4^-hvdroxy- 1 -[25-(26'-methylamino-propionylamino)-butyryll- pyrrolidin-2i?-yl-J7-methyl}-lH,rH-[2,2']biindolyl-3-yl-(ij-methyl)-45'-hvdroxy-pyrrolidine- 1 -carbonyl] -propyl I -25'-methylamino-propionamide (29): To a solution containing crude 28 (0.15 mmol) in MeOH (20 mL) was added 1 M NaOH (5 mL) at 0 0C. The reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine and dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product-containing fractions were combined, concentrated, and lyophilized to afford 110 mg of 29 (90%, 2 steps) as a fiocculent, white-colored solid. 1H NMR (300 MHz, CDCl3 + d4-MeOH), mixture of rotomers: δl l .58 (s, 2H), 7.80 (dd, J = 5.4, 8.7 Hz, 2H), 7.45 (dd, J =2.4, 9.9 Hz, 2H), 6.87 (ddd, J= 2.4, 9.2, 9.2 Hz, 2H), 4.66 (dd, J= 5.7, 7.8 Hz, 2H), 4.60 (br s, 2H), 4.47 (d, J= 7.2 Hz, 2H), 4.00 (dd, J= 4.8, 11.4 Hz, 2H), 3.76 (d, J= 11.4 Hz, 2H), 3.43 (q, J= 6.9 Hz, 2H), 2.55 (s, 6H), 2.19 (d, J= 14.4 Hz, 2H), 1.78-2.02 (m, 8H), 1.46 (d, J= 7.2 Hz, 6H), 1.09 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3 + J4-MeOH), mixture of rotomers: 5173.6, 171.8, 161.7, 158.6, 137.1, 136.9, 128.1, 128.0, 125.9, 119.8, 119.7, 108.3, 108.2, 107.8, 97.8, 97.5, 70.9, 69.4, 59.0, 56.1, 52.0, 36.3, 35.7, 25.5, 18.5, 9.8 ppm. Mass spectrum (ESI), m/z 811.4 [(M)+; calcd for C42H52D4F2N8O6: 810.9].
Scheme XXVIII
Figure imgf000037_0001
Acetic acid 5-(3'-{4-acetoxy-l-r2-(2-Jrmethyl-(tert-butoxycarbonyl)-amino- propionylamino)-butyryl]-pyrrolidin-2-yl-J7-methyll-6,6'-difluoro-lH,rH-[2,2'lbiindolyl-3- yl-^-methyl)-l-[2-(2-Jj-methyl-(tert-butoxycarbonyl)-ammo-propionylamino)-butyryl]- pyrrolidin-3-yl ester (30): To a solution containing BoC-N(J3-Me)AIa-OH (17, 83 mg, 0.41 mmol) and HATU (172 mg, 0.45 mmol) in anhydrous NMP (5 mL) at 0 0C was added NMM (0.1 mL, 0.85 mmol) followed by addition of crude 26 (123 mg, 0.17 mmol) in NMP (5 mL). The resulting mixture was allowed to warm to ambient temperature. After 16 h, the reaction mixture was diluted with diethyl ether (100 mL) and washed successively with water (50 mL), IN HCl (2 x 50 mL), saturated aqueous NaHCO3 (2 x 50 mL), brine, dried over anhydrous Na2SO4, filtered, concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" C18 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product-containing fractions were combined, concentrated, and lyophilized to afford 160 mg of 30 (85%, 2 steps) as a fiocculent, white-colored solid. 1H NMR (300 MHz, CDCl3), mixture of rotomers: δl 1.51 (br s, 2H), 7.40-7.60 (m, 4H), 6.87 (ddd, J = 2.1, 9.0, 9.0 Hz, 2H), 5.47 (t, J = 4.8 Hz, 2H), 4.74 (br s, 2H), 4.65 (q, J = 7.2 Hz, 2H), 4.46 (d, J = 8.1 Hz, 2H), 4.18 (dd, J = 3.9, 1 1.7 Hz, 2H) 3.83 (d, J = 12.3 Hz, 2H), 2.30 (s, 6H), 2.24 (m, 2H), 2.05 (m, 2H), 1.93 (m, 2H), 1.79 (m, 2H), 1.49 (s, 18H), 1.38 (d, J = 6.9 Hz, 6H), 1.02 (t, J = 7.2 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3), mixture of rotomers: 5175.6, 172.2, 172.1, 170.6, 161.8, 158.7, 137.5, 137.3, 128.5, 128.4, 125.8, 118.7, 118.6, 108.7, 108.4, 108.0, 98.8, 98.4, 81.1, 74.6, 66.1, 59.9, 54.0, 52.1, 33.7, 28.6, 27.5 (br), 25.8, 21.6, 20.9, 14.0, 9.9 ppm; Mass spectrum (ESI), m/z 1101.5 [(M)+; calcd for C56H66D10F2N8O12: 1101.3].
Scheme XXIX
Figure imgf000038_0001
Acetic acid 5-(3'- {4-acetoxy-l -[2-(2-<jj-methylamino-propionylamino)-butyryl]-pyrrolidin-2- yl-J2-methvU-6.6'-difluoro-lHJΗ-[2,2Hbiindolyl-3-yl-J2-me1hyl)-l-r2-('2-a?j-methylamino- propionylaminoVbutyryl]-pyrrolidin-3-yl ester (31): A solution containing 30 (160 mg, 0.14 mmol) in DCM (15 mL) was cooled to 0 0C. TFA (5 mL) was added. After 30 min, the reaction mixture was warmed to ambient temperature and monitored until LC/MS analysis revealed complete conversion of 30 to 31 (ca. 4 h). The solvent was removed in vacuo and the dark, green-colored residue was dissolved in EtOAc (100 mL) and carefully poured onto an aqueous NaHCO3/ice mixture. The aqueous phase was separated and back-extracted with EtOAc (2 x 20 mL). The combined organic extracts were washed several times with saturated aqueous NaHCO3, then brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford crude 31 as a light yellow-colored solid. Mass spectrum (ESI), m/z 901.5 [(M)+; calcd for C46H50D10F2N8O8: 901.1]. Scheme XXX
Figure imgf000039_0001
N-{lS-r2/--f6,6'-Difluoro-3'-{4S-hvdroxy-l-[2S-(25-methylamino-propionylamino)-butyryll- pytτolidin-2i.-yl-(J2-methvU-lHaΗ-[2.2Hbiindolyl-3-yl-d'7-methyl")-45'-hvdroxy-ρyrrolidine- 1 -carbonyl] -propyl } -2tS'-methylamino-propionamide (32) : To a solution containing crude 31 (0.14 mmol) in MeOH (20 mL) was added 1 M NaOH (5 mL) at 0 0C. The reaction mixture was degassed and maintained under a nitrogen atmosphere wrapped with aluminum foil. The ice-bath was removed. After 60 min, the MeOH was removed in vacuo and the residue was diluted with water (20 mL) and extracted with EtOAc (50 mL). The aqueous phase was separated and back-extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine and dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by reverse-phase HPLC (Dynamax 2" Cl 8 column; 10-100% ACN/water containing 0.1% HOAc over 30 min; 40 mL/min). The product-containing fractions were combined, concentrated, and lyophilized to afford 100 mg of 32 (87%, 2 steps) as a flocculent, white-colored solid. 1H NMR (300 MHz, CDCl3 + CI4-MQOH), mixture of rotomers: δ 11.62 (s, 2H), 7.79 (dd, J= 5.4, 8.4 Hz, 2Ii), 7.47 (dd, J= 2.4, 10.2 Hz, 2H), 6.87 (ddd, J = 2.4, 9.2, 9.2 Hz, 2H), 4.68 (dd, J= 5.4, 7.5 Hz, 2H), 4.58 (m, 2H), 4.45 (d, J = 6.6 Hz, 2H), 3.99 (dd, J = 4.8, 11.1 Hz, 2H), 3.75 (d, J= 11.1 Hz, 2H), 3.19 (q, J- 6.9 Hz, 2H), 2.15 (br d, J = 12 Hz, 2H), 1.78-2.02 (m, 8H), 1.39 (d, J = 6.6 Hz, 6H), 1.07 (t, J = 7.5 Hz, 6H) ppm; 13C NMR (75 MHz, CDCl3 + ^-MeOH), mixture of rotomers: 6175.4, 172.0, 161.8, 158.7, 137.1, 137.0, 128.2, 128.0, 126.0, 119.9, 119.7, 108.4, 108.3, 107.9, 98.0, 97.6, 71.0, 60.0, 59.6, 56.2, 51.6, 36.4, 25.8, 19.5, 9.8 ppm; Mass spectrum (ESI), m/z 817.4 [(M)+; calcd for C42H46Di0F2N8O6: 817.0].
Examples 2, 3, 4, and 5
Compounds tested in Examples 2, 3, 4, and 5 are shown in Table 1. Table 1
Figure imgf000040_0001
Figure imgf000040_0002
Example 2A. cIAP Degradation Assay
The concentration inducing degradation of cIAP-1 and cIAP-2 by 50% (IC50) for various compounds was determined by monitoring the disappearance of Green Fluorescent Protein (GFP)-signal in A375 cells. Briefly, A375 cell lines expressing GFP-tagged cIAP-1 and cIAP-2 were generated by transfecting HA2xEGFP-pcDNA3 vector containing either cIAP-1 (A375Gcl) or cIAP-2 (A375Gc2) coding region. 2xlO4 of A375Gcl or A375Gc2 cells were grown in 96-well plate and treated with various concentrations of test compounds for 2 h. After incubation, cells were collected by trypsinization and suspended in 150 μl of DMEM- 10% FBS. A total of 104 cells were analyzed using a FACScan (Becton Dickinson). GFP fluorescence was monitored by using an excitation filter at 488 nm and emission was measured with a 530 nm filter. IC50 is defined as the concentration of drug at which 50% of GFP signal was inhibited.
Results of the cIAP-1 and -2 degradation assay are shown in Table 2.
Table 2
Figure imgf000040_0003
Figure imgf000041_0001
These data show that Compound 15 has greater relative potency in degrading cIAP-1 relative to cIAP-2 when compared to Compounds 2, 3, 4, and 5.
Example 2B. Caspase-3 Derepression Assay
Exponentially growing MDA-MB-231 tumor cells (ATCC) were harvested by trypsinization and collected by centrifugation in a table top centrifuge at 1000xg for 10 minutes at room temperature. Cell pellet was washed one time by resuspending in 5 mL hypotonic lysis buffer (20 mM HEPES, pH7.5, 10 mM KCl, 1.5 mM MgCl2, 1.0 mM EDTA, 1.0 mM DTT) and recollected by centrifugation. Pellet was next resuspended in 1 volume of hypotonic lysis buffer supplemented with a complete protease inhibitor tablet (Roche) and allowed to swell on ice for 30 minutes. Cells were disrupted by approximately 50 passages through a 27 gauge needle. Lysis was monitored by light microscopy. Lysate was centrifuged at 12000xg for 10 minutes at 4°C to remove membrane fraction, unlysed cells and debris. The soluble fraction was collected for protein concentration determination and subsequent assay analysis. The hypotonic lysate (25 μg protein), 50 μg/mL cytochrome c and 10 mM dATP were combined in a microcentrifuge tube to a final volume of 9 μl in hypotonic lysis buffer followed by addition of test compound and incubated for 30 minutes at room temp.
Following incubation 50 μl of hypotonic lysis buffer containing 5 μM of pro-fluorescent rhodamine-110(2) based caspase-3 substrate zDEVD-Rl 10(2) was added and fluorescence intensity was monitored over time. Activation of the lysate by addition of cytochrome c and dATP results in apoptosome formation and subsequent activation of caspases-9 and -3.
Endogenous XIAP inhibits much of this activity and addition of test compound to the activated lysate results in more caspase activity than is generated by activated lysate alone as measured by increase in fluorescence intensity upon cleavage of zD E VD-Rl 10(2) by caspase- 3. IC50 values were calculated using GraphPad Prism by plotting increase in fluorescence intensity vs. different concentrations of compounds tested and the results are shown in Table 3. Table 3
Figure imgf000042_0001
These data show that Compound 15 has a lower potency for antagonizing XIAP function in comparison to Compounds 2, 3, 4, and 5.
Example 3 - Cytotoxicity
SKO V-3 ovarian tumor cell cytotoxicity data were generated substantially as follows. The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is an example of an assay that has been used for measuring cell growth as previously described (Hansen, M. B., Nielsen, S. E., and Berg, K. (1989) J. Immunol. Methods 119, 203-210) and incorporated herein by reference in its entirety. Briefly, SK-OV-3 cells were seeded in 96- well plates in McCoy's medium containing 10% fetal bovine serum albumin (5,000 per well) and incubated overnight at 37°C. The next day, test compounds were added at various concentrations (0.003-10 μM) and the plates were incubated at 37°C for an additional 72 hrs. This incubation time was optimal for measuring inhibitory effects of different analogs. Fifty microliters of 5mg/mL MTT reagent to each well was added and the plates were incubated at 37°C for 3 hours. At the end of the incubation period, 50 microliters of DMSO was added to each well to dissolve cells and the optical density (OD) of the wells was measured using a microplate reader (Victor2 1420, Wallac, Finland) at 535 nm. Cell survival (CS) was calculated by the following equation:
CS = (OD treated well/ mean OD control wells) X 100%
The CC50, defined as the drug concentration that results in 50% CS, was derived by calculating the point where the dose-response curve crosses the 50% CS point using
GraphPad Prism. These results suggest that Smac mimetics that bind to cIAP-1 can be used in the treatment of cancer either as monotherapy or in combination with chemofherapeutics. The results of SKO V- 3 cytotoxicity assays for the compounds tested in this assay are shown in Table 4.
Table 4
Figure imgf000043_0001
These data indicate that Compound 15 has equivalent potency to Compound 5 and is more potent than Compounds 2, 3, and 4.
Example 4 - Toxicity
Body weight loss (BWL), mortality and additional toxicity data were generated substantially as follows. Sprague-Dawley rats were dosed daily (QDx4, i.v. bolus slow push) with
Compounds 15, 4 and 5. Body weights were taken on day 4 and are shown as percent change from day 1. Compounds 4 and 5 were administered at 0.3 mg/Kg, 1 mg/Kg, or 3 mg/Kg;
Compound 15 was administered at 1 , 5, or 10 mg/Kg.
The results of the BWL assay are shown in Fig 1.
Mortality. Compounds 4 and 5 were not tolerated at 3 mg/Kg, and caused the animals to die at this dose. No mortality was observed with Compound 15 at 5 mg/Kg (mortality was observed at 10 mg/Kg.)
Clinical Results. There were no clinical signs noted at 1 mg/kg/day with Compound 15 after
4 days of administration. Animals treated with Compound 15 at 5 mg/kg/day exhibited clinical signs similar to Compounds 4 and 5 at 1 mg/kg/day such as lethargy,
increased/irregular respiration and increased heart rate. Rats treated with 1 mg/kg Compound
5 exhibited additional clinical observations including dehydration, ungroomed appearance, chromorhinorrhea, alopecia (head), and excessive scratching from days 2 to 4.
Body Weight. At 1 mg/Kg, animals receiving Compounds 4 and 5 lost weight whereas animals receiving Compound 15 at 1 mg/kg/day gained weight. At 5 mg/kg/day with Compound 15, a treatment related mean body weight loss of approximately 8% was noted from day 1 to day 4. A treatment-related mean body weight loss of approximately 4 % and 6 % was noted in animals treated with Compounds 4 and 5, respectively, at 1 mg/kg/day. Pathology. Assessment of anatomic pathology after treatment with Compounds 4 and 5 at 1 mg/kg/day resulted in the following findings. There was marked to severe bone marrow hypocellularity of the erythroid series, mild to moderate hypercellularity of the myeloid series, and mild to moderate hypertrophy and hyperplasia of megakaryocytes in the tibia and sternum when Compounds 4 and 5 were administered at 1 mg/kg/day. For Compounds 4 and 5 the lungs had dose-related mild to moderate diffuse hypertrophy/hyperplasia of Type 2 pneumocytes which were accompanied by an increase in alveolar macrophages,
hypertrophied bronchiolar epithelium, proliferating perivascular mononuclear cells and hypertrophied visceral pleural cells. In contrast, assessment of anatomic pathology following treatment with Compound 15 at the same dose (1 mg/kg/day) identified minimal to mild hypocellularity of erythroid cells, minimal to mild hypercellularity of myeloid cells, and minimal Type 2 pneumocyte hypertrophy in the lungs.
The data described above indicate that Compound 15 is approximately 5-fold better tolerated in the rat as compared to Compounds 4 and 5 on a dose per dose basis.
Example 5 - Tumor Volume Reduction and Body Weight Change
MDA-MB-231 xenograft data were generated substantially as follows. MDA-MB-231 human breast tumor cells were injected into the mammary fat pad of female nude mice and dosing initiated twelve days later at an average tumor volume of approximately 148 mm3. No tumor burden was associated with this model based on lack of weight loss or animal morbidity in control groups. Mice were injected subcutaneously into the mammary fat pad with 1x107 cells suspended in 200μl of a 1 :1 HBSS: Matrigel solution ; injected cells were within nine passages of the original lot. Pre-study tumor volumes were recorded beginning approximately one week prior to the estimated start date. When tumors reached
approximately 150 mm3 animals are matched by tumor volume into treatment and control groups and dosing initiated (Day 0); mice are tagged and followed individually throughout the experiment. Animals were dosed by weight (0.01 mL per gram; 10 ml/Kg).
Beginning on Day 0, animals were observed daily and weighed twice weekly using a digital scale (Ohaus SP601); data including individual and mean gram weights (Mean We ± SD), mean percent weight change versus Day 0 (%vDo) and mean percent weight change versus prior measurement (%vD.x) were recorded for each group and plotted at study completion. Beginning on Day 0, tumor dimensions were measured twice weekly by digital caliper (Fowler Ultra-Cal IV) and data including individual and mean estimated tumor volumes (Mean TV ± SEM) recorded for each group; tumor volume was calculated using the formula: TV~ width' x length x 0.52. Individual mice reaching the designated study endpoint (an estimated tumor volume of approximately 1 cm3) were assigned a time to endpoint (TTE) value corresponding to that day; the tumor growth delay (TGD) study was concluded once all mice reach the study endpoint or sixty days following study initiation. At study completion, TGD and %TGD are calculated using the median TTE (MTTE) value for each treatment (T) group versus control (C) by the formulas: TGD(days)= T-C and %TGD=T-C/C xlOO, wherein T-C is the difference between MTTE-Treatment Group and MTTE-Control. Tumored animals not reaching the designated volume endpoint by study completion are considered long-term survivors (LTS) and assigned a TTE value corresponding to the final study day; tumor- free animals are not included in TGD calculations. A Log-rank test is used to determine statistically significant differences in overall survival experience between each treated group compared to control. Individual mice reporting a tumor volume <50% of the Day 0 measurement for two consecutive measurements over a seven day period were considered partial responders (PR). If the PR persisted until study completion, percent tumor regression (%TR) was determined using the formula: %TR= 1-Tf/ T1 xlOO; a mean value was calculated if multiple PR mice occurred in one group. Individual mice lacking palpable tumors (< 4x4 mm2 for two consecutive measurements over a seven day period) were classified as complete responders (CR); a CR that persisted until study completion was considered a tumor-free survivor (TFS); TFS animals are excluded from TGD calculations and statistical analysis. Statistical differences in MTTE values between control and treatment groups are compared using a Log Rank test.
Compound 15 was administered by i.p. injection alone at 20, 40 or 60 mg/Kg on a q3dx5 schedule (every three days for 5 cycles). T-C values of 22 days were calculated for these groups, all of which were found statistically significant compared with control (p=0.005, p<0.0001, or p=0.0001). In the 20 mg/Kg group, 6/10 mice were considered long-term survivors and partial tumor regression was reported in three mice. In the 40 mg/Kg group, 9/10 mice were considered long-term survivors and partial tumor regression was reported in three mice. In the 60 mg/Kg group, 8/10 mice were considered long-term survivors and partial tumor regression was reported in seven mice. Compound 5 was administered by i.p. injection alone at 15 mg/Kg on a q3dx5 schedule. A T-C value of 21 days was calculated for this group which was found to be statistically significant compared with control (p=0.002). In this group 3/10 mice were considered long- term survivors and partial tumor regression was reported in five mice. The efficacy of this dose level produced half the number of long term survivors as 20 mg/Kg of Compound 15. The results of the MDA-MB-231 xenograft assay are shown in Figures 2A and 2B.
Compound 15 at 20 mg/Kg had comparable anti-tumor activity to Compound 5 at 15 mg/Kg. Subsequent studies have shown that the minimal effective dose of Compound 15 in this model is less than 1 mg/Kg. Weight loss was greater in the mice administered Compound 5 at 15 mg/Kg when compared to the mice dosed with Compound 15 at 20 mg/Kg. Thus, Compound 15 has comparable efficacy with less toxicity relative to Compound 5 and therefore has an improved therapeutic index.
The compound of Formula 1 is particularly well tolerated and well suited for use in a pharmaceutical composition, as well as in a method for treating a proliferative disorder or an autoimmune disorder. In particular, the pharmaceutical composition of the invention for the treatment of a proliferative disorder, which comprises an effective amount of Compound 15 in addition to at least one pharmaceutically acceptable excipient, can improve therapeutic index by reducing toxicities. The reduced toxicities include, e.g., one of, or any combination of one or more of:
• reduced body weight loss,
• decreased incidence of mortality,
• reduced bone marrow hypocellularity of the erythroid series,
• reduced hypercellularity of the myeloid series,
• reduced hypertrophy and hyperplasia of megakaryocytes,
• reduced diffuse hypertrophy/hyperplasia of Type 2 pneumocytes
• decreased lethargy,
• more regular respiration,
• lessened increase in heart rate.
The reduced toxicities listed above are those observed in the animals tested. Similar, additional, or different reduced toxicities will be observed in humans. The reductions are relative, e.g., relative to the extent that toxicities would be observed following internal administration of a pharmaceutical composition in which the active pharmaceutical ingredient is an analog of Compound 15, e.g., one or more of the analogs in which R5 is -CH2CH3, - CH(CH3)CH3, -tf-CH(OH)CH3, -S-CH(OH)CH3, and -7?-CH(OCH3)CH3, e.g., at the same dose or at a dose of comparable potency. It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

Claims:
1. A compound having the formula:
Figure imgf000048_0001
wherein R5 is -CH2CH3, or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound having the formula:
Figure imgf000048_0002
wherein R5 is -CH2CH3, or a pharmaceutically acceptable salt thereof, and a
pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 for the treatment of a proliferative disorder.
4. The pharmaceutical composition of claim 2 for the treatment of a cancer.
5. The pharmaceutical composition of claim 2, 3, or 4 which is a sterile liquid for injection.
6. The pharmaceutical composition of claim 2, 3, 4, or 5 which is in a unit dose form.
7. A method of treating a proliferative disorder in a mammal in need thereof that comprises internally administering to the animal an effective amount of Compound 15.
8. The method of claim 7 wherein the proliferative disorder is a cancer selected from the group consisting of: lung adenocarcinoma, pancreatic cancer, colon cancer, ovarian cancer, breast cancer, mesothelioma, peripheral neuroma, bladder cancer, glioblastoma, melanoma, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, bladder cancer,
meningioma, glioma, astrocytoma, breast cancer, cervical cancer, chronic myeloproliferative disorders (e.g., chronic lymphocytic leukemia, chronic myelogenous leukemia), colon cancer, endocrine cancers, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, extracranial germ cell tumors, extragonadal germ cell tumors, extrahepatic bile duct cancer, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gestational trophoblastic tumors, hairy cell leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, laryngeal cancer, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, Hp cancer, oral cavity cancer, liver cancer, male breast cancer, malignant mesothelioma, medulloblastoma, melanoma, Merkel cell carcinoma, metastatic squamous neck cancer, multiple myeloma and other plasma cell neoplasms, mycosis fungoides and the Sezary syndrome, myelodysplastic syndromes, nasopharyngeal cancer, neuroblastoma, non-small cell lung cancer, small cell lung cancer, oropharyngeal cancer, bone cancers, including osteosarcoma and malignant fibrous histiocytoma of bone, ovarian epithelial cancer, ovarian germ cell tumors, ovarian low malignant potential tumors, pancreatic cancer, paranasal sinus cancer, parathyroid cancer, penile cancer, pheochromocytoma, pituitary tumors, prostate cancer, rectal cancer, renal cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small intestine cancer, soft tissue sarcoma, supratentorial primitive neuroectodermal tumors, pineoblastoma, testicular cancer, thymoma, thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, and Wilm's tumor and other childhood kidney tumors.
9. The method of claim 7 wherein the proliferative disorder is a cancer selected from the group consisting of: sarcomas, bladder cancer, ovarian cancer, breast cancer, brain cancer, pancreatic cancer, colon cancer, blood cancer, skin cancer, lung cancer, and bone cancer.
10. The method of claim 7 wherein the cancer is selected from colorectal cancer, renal carinoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, breast carcinoma, melanoma, gliobastoma, acute myeloid leukemia, small cell lung cell carcinoma, non-small cell lung carcinoma, rhabdomyosarcoma, and basal cell carcinoma.
11. A method for inducing apoptosis in a cell comprising contacting the cell with
Compound 15 or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 wherein the cell is a cancer cell.
13. The method of any one or more of claims 7 through 12 that comprises administering Compound 15 in combination with a second cancer therapy selected from radiation, chemotherapy, immunotherapy, photodynamic therapy, and combinations thereof.
14. A method of treating an autoimmune disease, in a mammal in need thereof, wherein the autoimmune disease is one in which the condition is caused or exacerbated by abnormal regulation of apoptosis and is selected from the group consisting of: systemic lupus erythematosus, psoriasis, and idiopathic thrombocytopenic purpura (Morbus Werlhof) that comprises internally administering to the animal an effective amount of Compound 15 or a pharmaceutically acceptable salt thereof.
15. A compound selected from the group consisting of Compound 9, Compound 10, Compound 11, Compound 12, Compound 13, and Protected Compound 15.
16. The compound of claim 15 that is Compound 14.
17. A process for preparing Compound 15 that comprises deprotecting a Protected Compound 15.
18. The process of claim 17 wherein the Protected Compound 15 is Compound 14.
19. A compound selected from the group consisting of Compound 19, Compound 20, Compound 28, Compound 29, Compound 31. and Compound 32.
PCT/US2010/039976 2009-07-02 2010-06-25 Smac mimetic WO2011002684A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AP2012006066A AP3619A (en) 2009-07-02 2010-06-25 Smac mimetic
ES10794587.5T ES2565337T3 (en) 2009-07-02 2010-06-25 SMAC mimetic
EP10794587.5A EP2448923B8 (en) 2009-07-02 2010-06-25 Smac mimetic
MX2011013819A MX2011013819A (en) 2009-07-02 2010-06-25 Smac mimetic.
CN201080031798.6A CN102471275B (en) 2009-07-02 2010-06-25 SMAC mimetic
US13/382,075 US20120115922A1 (en) 2009-07-02 2010-06-25 Smac mimetec
DK10794587.5T DK2448923T3 (en) 2009-07-02 2010-06-25 SMAC mimetic
SG2011096948A SG177404A1 (en) 2009-07-02 2010-06-25 Smac mimetic
UAA201200409A UA108358C2 (en) 2009-07-02 2010-06-25 MIMETİK SMAS
AU2010266525A AU2010266525C1 (en) 2009-07-02 2010-06-25 SMAC mimetic
BRPI1013958-3A BRPI1013958B1 (en) 2009-07-02 2010-06-25 smac mimetic compounds for the treatment of proliferative disorders including cancers, pharmaceutical composition comprising said compounds and therapeutic uses thereof, as well as process for preparing a smac mimetic compound
NZ597051A NZ597051A (en) 2009-07-02 2010-06-25 Smac mimetic
EA201171494A EA022061B1 (en) 2009-07-02 2010-06-25 Smac mimetic
KR1020127001113A KR101755218B1 (en) 2009-07-02 2010-06-25 SMAC mimetic
JP2012518560A JP5674780B2 (en) 2009-07-02 2010-06-25 SMAC mimic
CA2766162A CA2766162C (en) 2009-07-02 2010-06-25 Smac mimetic
ZA2011/09342A ZA201109342B (en) 2009-07-02 2011-12-19 Smac mimetic
IL217237A IL217237A (en) 2009-07-02 2011-12-27 Smac mimetic compounds, compositions comprising the same and uses thereof
HK12110211.8A HK1169410A1 (en) 2009-07-02 2012-10-16 Smac mimetic smac
HK12111923.5A HK1171022A1 (en) 2009-07-02 2012-11-22 Smac mimetic smac

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22266809P 2009-07-02 2009-07-02
US61/222,668 2009-07-02
US12/819,221 2010-06-20
US12/819,221 US8283372B2 (en) 2009-07-02 2010-06-20 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Publications (1)

Publication Number Publication Date
WO2011002684A1 true WO2011002684A1 (en) 2011-01-06

Family

ID=43411387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039976 WO2011002684A1 (en) 2009-07-02 2010-06-25 Smac mimetic

Country Status (27)

Country Link
US (10) US8283372B2 (en)
EP (1) EP2448923B8 (en)
JP (1) JP5674780B2 (en)
KR (1) KR101755218B1 (en)
CN (1) CN102471275B (en)
AP (1) AP3619A (en)
AR (1) AR077629A1 (en)
AU (1) AU2010266525C1 (en)
BR (1) BRPI1013958B1 (en)
CA (1) CA2766162C (en)
CL (1) CL2011003333A1 (en)
CO (1) CO6480975A2 (en)
DK (1) DK2448923T3 (en)
EA (1) EA022061B1 (en)
EC (1) ECSP11011557A (en)
ES (1) ES2565337T3 (en)
HK (2) HK1169410A1 (en)
HU (1) HUE026982T2 (en)
IL (1) IL217237A (en)
MX (1) MX2011013819A (en)
MY (1) MY153116A (en)
NZ (1) NZ597051A (en)
PE (1) PE20131173A1 (en)
SG (1) SG177404A1 (en)
TW (1) TWI485148B (en)
WO (1) WO2011002684A1 (en)
ZA (1) ZA201109342B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049350A1 (en) * 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US8445440B2 (en) 2010-02-25 2013-05-21 Novartis Ag Dimeric IAP inhibitors
US8791255B2 (en) 2009-07-02 2014-07-29 Sanofi (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
JP2015524441A (en) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション Combination therapy
US10508103B2 (en) 2016-04-27 2019-12-17 Medshine Discovery Inc. Benzimidazole-linked indole compound acting as novel divalent IAP antagonist
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
WO2021020585A1 (en) 2019-07-31 2021-02-04 ファイメクス株式会社 Heterocyclic compound
WO2022130411A1 (en) * 2020-12-17 2022-06-23 Council Of Scientific & Industrial Research Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (en) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション IAP binding compound
EA012810B1 (en) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Dimeric iap inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
UY33794A (en) 2010-12-13 2012-07-31 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
EP3682873B1 (en) 2013-06-25 2024-06-12 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
US20160161495A1 (en) * 2013-07-30 2016-06-09 Health Researc Inc. Method of Treatment
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3419643A4 (en) * 2016-02-24 2020-04-01 Children's Hospital of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2019080928A1 (en) * 2017-10-27 2019-05-02 南京明德新药研发股份有限公司 Crystal form of iap antagonist and preparation method therefor
WO2019089991A1 (en) * 2017-11-01 2019-05-09 The Regents Of The University Of California Novel agents targeting inhibitor of apoptosis proteins
US10944377B2 (en) * 2017-12-31 2021-03-09 Skyworks Solutions, Inc. Broadband power splitter
CN111655713B (en) * 2018-02-09 2023-06-27 广东东阳光药业有限公司 IAP inhibitor and application thereof in medicines
CN112521372B (en) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 Apoptosis protein inhibitor and preparation method and application thereof
CN112778398A (en) * 2019-11-07 2021-05-11 杜心赟 Liver-targeting drug, pharmaceutical composition thereof and application thereof
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2023194547A1 (en) 2022-04-08 2023-10-12 Medivir Ab Birinapant polymorph h
TW202410919A (en) 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5 agonist and iap antagonist combination therapy
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194741A1 (en) * 2005-02-25 2006-08-31 Condon Stephen M Dimeric IAP inhibitors
US20080119532A1 (en) * 2004-03-01 2008-05-22 Board Of Regents, The University Of Texas System Dimeric Small Molecule Potentiators of Apoptosis

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
DE2714880A1 (en) 1977-04-02 1978-10-26 Hoechst Ag CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
DE3174064D1 (en) 1980-10-15 1986-04-17 Takeda Chemical Industries Ltd Method for immunochemical assay and kit therefor
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4525300A (en) 1983-01-07 1985-06-25 Japanese Foundation For Cancer Research Human leukemia virus-related peptides, antibodies of the peptides and a process for production of the antibodies
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5208007A (en) 1988-11-22 1993-05-04 Board Of Regents Of The University Of Oklahoma Isotopic tracer composition and method for making and using same
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5545719A (en) 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
JPH04167172A (en) 1990-10-31 1992-06-15 Nec Corp Vector processor
DE4105480A1 (en) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh IMPROVED ACTIVATION OF RECOMBINANT PROTEINS
US5831002A (en) 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
ES2130406T5 (en) 1992-08-05 2003-12-16 Meito Sangyo Kk COMPOSITE MATERIAL OF SMALL DIAMETER COMPOSITE OF CARBOXIPOLISACARIDO SOLUBLE IN WATER AND MAGNETIC IRON OXIDE.
WO1994013698A1 (en) 1992-12-11 1994-06-23 University Of Florida Materials and methods for control of pests
US5468494A (en) 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5527775A (en) 1994-10-13 1996-06-18 Enzon, Inc. Reduction of mammalian neoplasms with phospholipase A2 activating substances
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5786173A (en) 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US6133437A (en) 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5977311A (en) 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
AU2001293189A1 (en) 2000-09-29 2002-04-08 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
EP1421204A4 (en) 2001-05-31 2004-12-15 Univ Princeton Iap binding peptides and assays for identifying compounds that bind iap
AU2002323368B2 (en) 2001-08-23 2006-12-07 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
CN101029080A (en) 2001-11-21 2007-09-05 伯纳姆研究院 Methods and compositions for derepression of IAP-inhibited caspase
BR0312408A (en) 2002-07-02 2005-04-19 Novartis Ag Protein-binding peptide inhibitors smac to protein apoptosis inhibitor (iap)
ATE415413T1 (en) 2002-07-15 2008-12-15 Univ Princeton IAP BINDING COMPOUNDS
US7149755B2 (en) 2002-07-29 2006-12-12 Hewlett-Packard Development Company, Lp. Presenting a collection of media objects
US20080199439A1 (en) 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2553871A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
WO2005069894A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
BRPI0507482A (en) 2004-02-05 2007-07-17 Novartis Ag combination of (a) a dna topoisomerase inhibitor and (b) a iap inhibitor
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
EP2065368A1 (en) 2004-04-07 2009-06-03 Novartis Ag Inhibitors of IAP
PT1778718E (en) 2004-07-02 2014-12-03 Genentech Inc Inhibitors of iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
JP5230865B2 (en) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション IAP binding compound
JP2008016458A (en) 2004-08-18 2008-01-24 Teijin Ltd Electromagnetic wave absorbing sheet material
DE602005022936D1 (en) 2004-12-20 2010-09-23 Genentech Inc PYRROLIDINES AS INHIBITORS OF IAP
US20060228352A1 (en) * 2005-02-24 2006-10-12 Schoenberger Stephen P TRAIL and methods of modulating T cell activity and adaptive immune responses using TRAIL
CN101128425B (en) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Dimeric IAP inhibitors
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
US7763604B2 (en) 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
JP4954983B2 (en) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド BIR domain binding compound
AU2006254538A1 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
KR20080022092A (en) 2005-06-08 2008-03-10 노파르티스 아게 Organic compounds
US20070203749A1 (en) 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders
AU2006279929A1 (en) 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
US8247557B2 (en) 2005-12-19 2012-08-21 Genentech, Inc. IAP inhibitors
EP1965865B1 (en) 2005-12-20 2018-05-16 Novartis AG Combination of an iap-inhibitor and a taxane
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (en) 2006-03-16 2015-10-21 Pharmascience Inc Iap bir domain binding compounds
CA2646186A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
US8202902B2 (en) 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
AU2007248473B2 (en) 2006-05-05 2011-01-27 The Regents Of The University Of Michigan Bivalent Smac mimetics and the uses thereof
CN101535300B (en) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir domain binding compounds
US20100144650A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
CN101516904A (en) * 2006-07-24 2009-08-26 泰特拉洛吉克药业公司 Dimeric IAP antagonists
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (en) 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
WO2008014236A1 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100143499A1 (en) 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110224A1 (en) 2006-08-02 2011-04-05 Novartis Ag PROCEDURE FOR THE SYNTHESIS OF A PEPTIDOMIMETIC OF Smac INHIBITOR OF IAP, AND INTERMEDIARY COMPOUNDS FOR THE SYNTHESIS OF THE SAME
US20100316573A1 (en) 2006-10-19 2010-12-16 Larry Alexander Gaither Organic Compounds
JP2010513561A (en) 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド IAP imidazopyridine inhibitors
BRPI0810178A2 (en) 2007-04-12 2014-09-23 Joyant Pharmaceuticals Inc SMAC MIME DIMERS AND THERMALS USEFUL AS ANTICCAN AGENTS
WO2008134679A1 (en) 2007-04-30 2008-11-06 Genentech, Inc. Inhibitors of iap
CA2686638A1 (en) 2007-05-07 2008-11-13 Tetralogic Pharmaceuticals Corp. Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
CN101951766A (en) 2008-01-24 2011-01-19 泰特拉洛吉克药业公司 IAP inhibitors
CA2736505A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
EP2382465A1 (en) 2009-01-29 2011-11-02 Otto-von-Guericke-Universität Magdeburg Method of determining sensitivity of human or non-human animal cells to an iap antagonist
CA2763614A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
EP2434890A4 (en) 2009-05-28 2013-01-02 Tetralogic Pharm Corp Iap inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
AU2012315986A1 (en) 2011-09-30 2014-04-17 Srinivas Chunduru Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
WO2014022612A1 (en) 2012-08-01 2014-02-06 Tetralogic Pharmaceuticals Corporation Combination therapy
WO2014121178A1 (en) 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
US20140303090A1 (en) 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119532A1 (en) * 2004-03-01 2008-05-22 Board Of Regents, The University Of Texas System Dimeric Small Molecule Potentiators of Apoptosis
US20060194741A1 (en) * 2005-02-25 2006-08-31 Condon Stephen M Dimeric IAP inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2448923A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791255B2 (en) 2009-07-02 2014-07-29 Sanofi (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
US8993565B2 (en) 2009-07-02 2015-03-31 Sanofi (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors
US8445440B2 (en) 2010-02-25 2013-05-21 Novartis Ag Dimeric IAP inhibitors
WO2013049350A1 (en) * 2011-09-30 2013-04-04 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20140243276A1 (en) * 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
JP2015524441A (en) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション Combination therapy
US10508103B2 (en) 2016-04-27 2019-12-17 Medshine Discovery Inc. Benzimidazole-linked indole compound acting as novel divalent IAP antagonist
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US11492361B2 (en) 2018-11-30 2022-11-08 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US11873310B2 (en) 2018-11-30 2024-01-16 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
WO2021020585A1 (en) 2019-07-31 2021-02-04 ファイメクス株式会社 Heterocyclic compound
WO2022130411A1 (en) * 2020-12-17 2022-06-23 Council Of Scientific & Industrial Research Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof

Also Published As

Publication number Publication date
US20150158908A1 (en) 2015-06-11
US20140073579A1 (en) 2014-03-13
AU2010266525C1 (en) 2015-10-01
AP2012006066A0 (en) 2012-02-29
BRPI1013958A2 (en) 2019-09-03
KR101755218B1 (en) 2017-07-07
KR20120047905A (en) 2012-05-14
HK1171022A1 (en) 2013-03-15
US10314881B2 (en) 2019-06-11
US11351221B2 (en) 2022-06-07
EA201171494A1 (en) 2012-06-29
SG177404A1 (en) 2012-02-28
CO6480975A2 (en) 2012-07-16
US8283372B2 (en) 2012-10-09
EP2448923B1 (en) 2015-11-25
US20190255139A1 (en) 2019-08-22
US20230149500A1 (en) 2023-05-18
EA022061B1 (en) 2015-10-30
US20200282002A1 (en) 2020-09-10
US20180303897A1 (en) 2018-10-25
EP2448923A4 (en) 2013-05-01
US8986993B2 (en) 2015-03-24
US20110003877A1 (en) 2011-01-06
EP2448923B8 (en) 2016-01-27
US20170182116A1 (en) 2017-06-29
JP2012532129A (en) 2012-12-13
TWI485148B (en) 2015-05-21
MY153116A (en) 2014-12-31
CN102471275B (en) 2014-05-28
CL2011003333A1 (en) 2012-07-20
US20120115922A1 (en) 2012-05-10
CA2766162C (en) 2018-07-24
ES2565337T3 (en) 2016-04-04
CA2766162A1 (en) 2011-01-06
EP2448923A1 (en) 2012-05-09
CN102471275A (en) 2012-05-23
BRPI1013958B1 (en) 2022-04-05
IL217237A (en) 2014-09-30
US10034912B2 (en) 2018-07-31
US10596220B2 (en) 2020-03-24
ECSP11011557A (en) 2012-06-29
HUE026982T2 (en) 2016-08-29
DK2448923T3 (en) 2016-02-29
AU2010266525A1 (en) 2012-01-19
TW201113276A (en) 2011-04-16
US8603816B2 (en) 2013-12-10
AU2010266525B2 (en) 2015-05-21
MX2011013819A (en) 2012-06-08
IL217237A0 (en) 2012-02-29
US20130012564A1 (en) 2013-01-10
AP3619A (en) 2016-02-29
ZA201109342B (en) 2014-05-28
AR077629A1 (en) 2011-09-14
NZ597051A (en) 2013-10-25
HK1169410A1 (en) 2013-01-25
JP5674780B2 (en) 2015-02-25
PE20131173A1 (en) 2013-10-03
US11951147B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
US11351221B2 (en) SMAC mimetic
AU2012315986A1 (en) Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
EP2493879A2 (en) Dimeric smac mimetics
OA16572A (en) Smac mimetic.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080031798.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10794587

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010266525

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 5014/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/013819

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2766162

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010794587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011003333

Country of ref document: CL

Ref document number: 2012518560

Country of ref document: JP

Ref document number: 201171494

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 11180821

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12012500009

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 13382075

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20127001113

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2010266525

Country of ref document: AU

Date of ref document: 20100625

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201200409

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 000215-2012

Country of ref document: PE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1013958

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1013958

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111229